EP1320540B9 - Inhibiteurs peptidomimetiques de protease - Google Patents
Inhibiteurs peptidomimetiques de protease Download PDFInfo
- Publication number
- EP1320540B9 EP1320540B9 EP01968040A EP01968040A EP1320540B9 EP 1320540 B9 EP1320540 B9 EP 1320540B9 EP 01968040 A EP01968040 A EP 01968040A EP 01968040 A EP01968040 A EP 01968040A EP 1320540 B9 EP1320540 B9 EP 1320540B9
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- mmol
- interferon
- hepatitis
- etoac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 *C1=CCCC1 Chemical compound *C1=CCCC1 0.000 description 44
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- IPGDQHSSAQJORG-UHFFFAOYSA-N C=CC1OC=CC=C1 Chemical compound C=CC1OC=CC=C1 IPGDQHSSAQJORG-UHFFFAOYSA-N 0.000 description 1
- RKMMYQDHNPGSRU-UHFFFAOYSA-N CC(C(C)(C)C)NCC=C Chemical compound CC(C(C)(C)C)NCC=C RKMMYQDHNPGSRU-UHFFFAOYSA-N 0.000 description 1
- OIJJKNROCZGQES-UHFFFAOYSA-N CC(C)(C(C1)CC2=NC3)C1C2(C)OC3=O Chemical compound CC(C)(C(C1)CC2=NC3)C1C2(C)OC3=O OIJJKNROCZGQES-UHFFFAOYSA-N 0.000 description 1
- XBTLHJYRKFOPJD-UHFFFAOYSA-N CC(C)(C)C(C=C)C(S(CC1C2CCC1)C2C(C)=O)=O Chemical compound CC(C)(C)C(C=C)C(S(CC1C2CCC1)C2C(C)=O)=O XBTLHJYRKFOPJD-UHFFFAOYSA-N 0.000 description 1
- KZUIBDQUHBMRQU-UHFFFAOYSA-N CC(C)C(C(C)CC(OCc1ccccc1)=O)C(O)=O Chemical compound CC(C)C(C(C)CC(OCc1ccccc1)=O)C(O)=O KZUIBDQUHBMRQU-UHFFFAOYSA-N 0.000 description 1
- VNVSKTAGVBZGSV-UHFFFAOYSA-N CC(C)C(C(c1ccccc1)=NC1)[Np]C1=O Chemical compound CC(C)C(C(c1ccccc1)=NC1)[Np]C1=O VNVSKTAGVBZGSV-UHFFFAOYSA-N 0.000 description 1
- GHDPVGYLFYKJKO-BVXQJTRBSA-N CC(C)[C@@H](C(N[C@@H](C(C)C)C(N(C1)[C@H](C[U+])C[C@H]1O)=O)=O)NC(c1nccnc1)=O Chemical compound CC(C)[C@@H](C(N[C@@H](C(C)C)C(N(C1)[C@H](C[U+])C[C@H]1O)=O)=O)NC(c1nccnc1)=O GHDPVGYLFYKJKO-BVXQJTRBSA-N 0.000 description 1
- UAEPNZWRGJTJPN-UHFFFAOYSA-N CC1CCCCC1 Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 1
- RUTNIWSMROZIHE-WOUDDHOMSA-O CCC[C@@H](C(C(NC1CC1)=O)=[U])N/C(/[OH2+])=C(\[C@@H](CCC1)[C@@H]1C1)/N1C(C(C(C)(C)C)NC(C1(CCCCC1)NC(/C(/NI)=C/N=[IH])=O)=O)=O Chemical compound CCC[C@@H](C(C(NC1CC1)=O)=[U])N/C(/[OH2+])=C(\[C@@H](CCC1)[C@@H]1C1)/N1C(C(C(C)(C)C)NC(C1(CCCCC1)NC(/C(/NI)=C/N=[IH])=O)=O)=O RUTNIWSMROZIHE-WOUDDHOMSA-O 0.000 description 1
- BDDYLYGWEZEQEZ-UHFFFAOYSA-N CCOC(C1NCC2C=CCC12)=O Chemical compound CCOC(C1NCC2C=CCC12)=O BDDYLYGWEZEQEZ-UHFFFAOYSA-N 0.000 description 1
- UUOPMKGRFPBIKY-UHFFFAOYSA-O CC[N](C)(C)C(CC(C(CI)[NH2+]C)=O)=O Chemical compound CC[N](C)(C)C(CC(C(CI)[NH2+]C)=O)=O UUOPMKGRFPBIKY-UHFFFAOYSA-O 0.000 description 1
- XWBPNQVDGRCVQN-QRVCZOOMSA-N C[C@@H](C1[C@H](C)C1)C1=CCC(C)C=C1 Chemical compound C[C@@H](C1[C@H](C)C1)C1=CCC(C)C=C1 XWBPNQVDGRCVQN-QRVCZOOMSA-N 0.000 description 1
- XXBQJWDNYRUJGB-OPLYHSBCSA-N C[O+](C1)[I]1C(C1[C@H]2CCC1)NC2=[U] Chemical compound C[O+](C1)[I]1C(C1[C@H]2CCC1)NC2=[U] XXBQJWDNYRUJGB-OPLYHSBCSA-N 0.000 description 1
- PXJLHPDPYGTFBZ-UHFFFAOYSA-N [O-][NH+](CC1)Cc2c1cccc2 Chemical compound [O-][NH+](CC1)Cc2c1cccc2 PXJLHPDPYGTFBZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- This invention is directed to peptidomimetic compounds and pharmaceutical compositions containing the peptidomimetic compounds, and the use of the peptidomimetic compounds or compositions thereof in the manufacture of a medicament for inhibiting protease, particularly serine protease and more particularly hepatitis C virus (“HCV”) NS3 protease.
- the peptidomimetic compounds, as HCV NS3 protease inhibitors, are particularly useful in interfering with the life cycle of the hepatitis C virus and in treating or preventing an HCV infection or physiological conditions associated therewith.
- the present invention is also directed to the use of the peptidomimetic compounds or pharmaceutical compositions or kits and pharmaceutical packs therefor in the manufacture of a medicament for combination therapy for inhibiting HCV replication in cells, or for treating or preventing an HCV infection in patients.
- included as pharmaceutical compositions are those comprising an inhibitor of HCV serine protease in combination with an interferon having anti-HCV activity; an inhibitor of HCV serine protease in combination with a compound, other than an interferon, having anti-HCV activity; or an inhibitor of HCV serine protease in combination with both an interferon having anti-HCV activity and a compound, other than an interferon, having anti-HCV activity.
- the peptidomimetic compounds may be prepared using stereoselective methods for preparing chiral bicycloprolinate intermediates useful in the synthesis of the peptidomimetic compounds.
- the HCV is thought to infect chronically 3% of the world's population [ A. Alberti et al., "Natural History of Hepatitis C, J. Hepatology, 31, (Suppl. 1), 17-24 (1999 )]. In the United States alone the infection rate is 1.8% or 3.9 million people [ M.J. Alter, Hepatitis C Virus Infection in the United States", J. Hepatology, 31, (Suppl. I), 88-91(1999 )]. Of all patients infected over 70% develop a chronic infection that is believed to be a major cause of cirrhosis and hepatocellular carcinoma. [ D. Lavanchy, "Global Surveillance and ContrXol of Hepatitis C, " J. Viral Hepatitis, 6, 35-47 (1999) ]
- the replication of the HCV encompasses genomic encoding a polyprotein of 30 10-3033 amino acids [ Q.-L. Choo, et al., "Genetic Organization and Diversity of the Hepatitis C Virus", Proc. Natl. Acad. Sci. USA, 88, 2451-2455 (1991) ; N. Kato et al., "Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis", Proc. Natl. Acad. Sci. USA, 87, 9524-9528 (1990) ; A. Takamizawa et al., "Structure and Organization of the Hepatitis C Virus Genome Isolated From Human Carriers", J.
- the HCV nonstructural (NS) proteins are presumed to provide the essential catalytic machinery for viral replication.
- the NS proteins are derived by proteolytic cleavage of the polyprotein [ R. Bartenschlager et al., "Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions", J. Virol., 67, 3835-3844 (1993) ; A. Grakoui et al.
- NS3 the first 181 amino acids of NS3 (residues 1027-1207 of the viral polyprotein) have been shown to contain the serine protease domain of NS3 that processes all four downstream sites of the HCV polyprotein [ C. Lin et al., "Hepatitis C Virus NS3 Serine Proteinase: Trans-Cleavage Requirements and Processing Kinetics", J. Virol., 68, 8147-8157 (1994) ].
- the HCV NS protein 3 (NS3) contains a serine protease activity that helps in the processing of the majority of the viral enzymes, and thus is considered essential for viral replication and infectivity.
- the essentiality of the NS3 protease was inferred from the fact that mutations in the yellow fever virus NS3 protease decreases viral infectivity [ T.J. Chambers et al., "Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein", Proc. Natl. Acad. Sci. USA, 87, 8898-8902 (1990) ]. More recently, it was demonstrated that mutations at the active site of the HCV NS3 protease could completely abolish the HCV infection in a chimpanzee model [ C.M. Rice et al.
- HCV NS3 serine protease is also considered essential for viral replication as it and its associated cofactor, NS4A, help in the processing of all of the viral enzymes. This processing appears to be analogous to that carried out by the human immunodeficiency virus (“HIV”) aspartyl protease.
- HIV human immunodeficiency virus
- the demonstrated use of HIV protease inhibitors as potent antiviral agents in man demonstrates that interrupting a protease protein processing stage in the viral life cycle does result in therapeutically active agents. Consequently, the protease enzyme is an attractive target for drug discovery.
- the present invention relates to compound or pharmaceutically acceptable salts and prodrugs thereof, solvates of such a compound, its salts and its prodrugs, and or pharmaceutically acceptable salts and prodrugs thereof, solvates of such a compound, its salts and its prodrugs.
- the invention is also directed to a pharmaceutical composition
- a pharmaceutical composition comprising a compound BW or CU and the use of compound BW or CU in the manufacture of a medicament for inhibiting HCV protease, or treating or preventing an HCV infection in patients or physiological condition related to the infection.
- Described is a stereoselective process for preparing a chiral bicycloprolinate compound that is an intermediate useful in preparing a compound BW and CU.
- the synthetic process comprises the steps of:
- the invention is also directed to the above synthetic process further comprising the step wherein the compound of formula 24 is prepared by effecting a Michael addition with an iminic glycinimide compound on a compound of formula 29 wherein: is optionally substituted cycloalkenyl or optionally substituted fused arylcycloalkenyl; R 11 is -CO 2 R 13 ; wherein:
- conversion of ketones to esters may be accomplished, for example, by a Bayer-Villiger reaction.
- Conversion of nitriles and amides to esters may be accomplished, for example, by aqueous hydrolysis followed by further esterification.
- Conversion of aldehydes to esters may be accomplished, for example, by oxidation of the aldehyde followed by esterification.
- compositions comprising, in addition to one or more of the HCV serine protease inhibitors BW and CU, one or more interferons or compounds that induce the production of interferons that exhibit anti-HCV activity and/or one or more compounds having anti HCV activity, including immunomodulatory compounds such as immunostimulatory cytokines exhibiting HCV antiviral activity, and a pharmaceutically acceptable carrier.
- Another aspect of the invention is the use of compounds BW and CU for the manufacture of a medicament for treating or preventing a HCV infection in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a combination of one or more of the HCV serine protease inhibitors BW and CU; one or more interferons or compounds that induce the production of an inteferon that exhibit anti-HCV activity; and/or one or more compounds having anti-HCV activity, including immunomodulatory compounds such as immunostimulatory cytokines exhibiting HCV antiviral activity.
- the invention is also directed to the use of one or more of the HCV serine protease inhibitors BW and CU in combination with one or more interferons or compounds that induce the production of an inteferon that exhibit anti-HCV activity and/or one or more compounds having anti-HCV activity, including immunomodulatory compounds such as immunostimulatory cytokines exhibiting HCV antiviral activity, to prepare a medicament for treating or preventing a HCV infection in a patient in need thereof.
- immunomodulatory compounds such as immunostimulatory cytokines exhibiting HCV antiviral activity
- the present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient, wherein the kit or pharmaceutical pack comprises a plurality of separate containers, wherein at least one of said containers contains one or more of the HCV serine protease inhibitors BW and CU (alone or in combination with a pharmaceutically acceptable carrier or diluent), at least another of said containers contains one or more interferons or compounds that induce the production of an inteferon that exhibit anti-HCV activity, (alone or in combination with a pharmaceutically acceptable carrier or diluent) and, optionally, at least another of said containers contains one or more compounds having anti-HCV activity (alone or in combination with a pharmaceutically acceptable carrier or diluent), including immunomodulatory compounds such as immunostimulatory cytokines exhibiting HCV antiviral activity.
- the kit or pharmaceutical pack comprises a plurality of separate containers, wherein at least one of said containers contains one or more of the HCV serine protease inhibitors BW and
- the amount of the HCV serine protease inhibitor(s), interferon(s), or anti-HVC compound(s) in any of the foregoing applications can be a pharmaceutically effective amount, a subclinical anti-HCV effective amount, or combinations thereof, so long as the final combination of HCV serine protease inhibitor(s), interferon(s), or compounds that induce the production of an interferon that exhibit anti-HCV activity, and/or anti-HCV compound(s) comprises a pharmaceutically effective amount of compounds that is effective in treating or preventing HCV infection in a patient.
- the nitrogen or sulfur atom of the heteroaryl or heterocyclyl portion of the fused heteroarylheterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
- exemplary fused heteroarylheterocyclenyl include 7,8-dihydro[1,7]napthyridinyl, 1,2-dihydro[2,7]-naphthyridinyl, 6,7-dihydro-3H-imidazo[4,5-c]pyridyl, 1,2-dihydro-1,5-naphthyridinyl.
- fused heteroarylheterocyclyl means a fused heteroaryl and heterocyclyl as defined herein.
- Preferred fused heteroarylheterocyclyls are those wherein the heteroaryl thereof consists of about 5 to about 6 ring atoms and the heterocyclyl consists of about 5 to about 6 ring atoms.
- a fused heteroarylheterocyclyl as a variable may be bonded through any atom of the ring system thereof capable of such.
- the designation of the aza, oxa or thia as a prefix before the heteroaryl or heterocyclyl portion of the fused heteroarylheterocyclyl define that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
- Substituted fused heteroarylheterocyclyl means a fused heteroarylheterocyclyl group as defined above which is substituted with one or more "ring group substituents" (preferably 1 to 3) which may be the same or different and are as defined herein.
- the nitrogen atom of a fused heteroarylheterocyclyl may be a basic nitrogen atom.
- the nitrogen or sulfur atom of the heteroaryl portion of the fused heteroarylheterocyclyl may also be optionally oxidized to the corresponding N-oxide.
- the nitrogen or sulfur atom of the heteroaryl or heterocyclyl portion of the fused heteroarylheterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
- exemplary fused heteroarylheterocyclyl include 2,3-dihydro-1H pyrrol [3,4-b]quinolin-2-yl, 1,2,3,4-tetrahydrobenz [b][1,7]naphthyridin-2-yl, 1,2,3,4-tetrahydrobenz [b][1,6]naphthyridin-2-yl, 1,2,3,4-tetra-hydro-9H-pyrido [3,4-b]indol-2yl, 1,2,3,4-tetrahydro-9H-pyrido [4,3-b]indol-2yl, 2,3-dihydro-1H-pyrrolo [3,4-b]indol-2-y
- Halo means fluoro, chloro, bromo, or iodo. Preferred are fluoro, chloro or bromo, and more preferred are fluoro or chloro.
- Heteroaroyl means a heteroaryl-CO- group wherein the heteroaryl group is as herein described.
- exemplary heteroaroyl groups include thiophenoyl, nicotinoyl, pyrrol-2-ylcarbonyl, 1- and 2-naphthoyl, pyridinoyl, and the like.”
- Heteroaryl means an aromatic monocyclic or multicyclic ring system of about 5 to about 14 carbon atoms, preferably about 5 to about 10 carbon atoms, in which one or more of the carbon atoms in the ring system is/are hetero element(s) other than carbon, for example nitrogen, oxygen or sulfur.
- the ring system includes 1 to 3 heteroatoms.
- Preferred ring sizes of rings of the ring system include about 5 to about 6 ring atoms.
- Encompassed by heteroaryl are fused heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl and fused heteroarylheterocyclyl as defined herein when bonded through the heteroaryl moiety thereof.
- Substituted heteroaryl means a heteroaryl group as defined above which is substituted with one or more "ring group substituents” (preferably 1 to 3) which may be the same or different and are as defined herein.
- ring group substituents preferably 1 to 3
- the designation of the aza, oxa or thia as a prefix before heteroaryl define that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
- a nitrogen atom of an heteroaryl may be a basic nitrogen atom and may also be optionally oxidized to the corresponding N-oxide.
- heteroaryl and substituted heteroaryl groups include pyrazinyl, thienyl, isothiazolyl, oxazolyl, pyrazolyl, furazanyl, pyrrolyl, 1,2,4-thiadiazolyl, pyridazinyl, quinoxalinyl, phthalazinyl, imidazo [1,2-a]pyridine, imidazo [2,1-b]thiazolyl, benzofurazanyl, azaindolyl, benzimidazolyl, benzothienyl, thienopyridyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, benzoazaindolyl, 1,2,4-triazinyl, benzthiazolyl, furanyl, imidazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl
- Heteroaryldiazo means a heteroaryl -azo- group wherein the heteroaryl and azo groups are as defined herein.
- Heteroarylidyl means a bivalent radical derived from a heteroaryl, wherein the heteroaryl is as described herein.
- An exemplary heteroaryldiyl radical is optionally substituted pyridinediyl.
- Heterocyclenyl means a non-aromatic monocyclic or multicyclic hydrocarbon ring system of about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms, in which one or more of the carbon atoms in the ring system is/are hetero element(s) other than carbon, for example nitrogen, oxygen or sulfur atoms, and which contains at least one carbon- carbon double bond or carbon-nitrogen double bond.
- the ring includes 1 to 3 heteroatoms.
- Preferred ring sizes of rings of the ring system include about 5 to about 6 ring atoms; and such preferred ring sizes are also referred to as "lower”.
- heterocyclenyl Encompassed by heterocyclenyl are fused arylheterocyclenyl and fused heteroarylheterocyclenyl as defined herein when bonded through the heterocyclenyl moiety thereof.
- the designation of the aza, oxa or thia as a prefix before heterocyclenyl define that at least a nitrogen, oxygen or sulfur atom is present, respectively, as a ring atom.
- “Substituted heterocyclenyl” means a heterocyclenyl group as defined above which is substituted with one or more "ring group substituents" (preferably 1 to 3) which may be the same or different and are as defined herein.
- the nitrogen atom of a heterocyclenyl may be a basic nitrogen atom.
- the nitrogen or sulfur atom of the heterocyclenyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
- exemplary monocyclic azaheterocyclenyl groups include 1,2,3,4-tetrahydrohydropyridine, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridine, 1,4,5,6-tetrahydro-pyrimidine, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, and the like.
- Exemplary oxaheterocyclenyl groups include 3,4-dihydro-2 H -pyran, dihydrofuranyl, and fluorodihydrofuranyl.
- An exemplary multicyclic oxaheterocyclenyl group is 7-oxabicyclo[2.2.1]heptenyl.
- Exemplary monocyclic thiaheterocyclenyl rings include dihydrothiophenyl and dihydrothiopyranyl.
- Heterocyclyl means a non-aromatic saturated monocyclic or multicyclic ring system of about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms, in which one or more of the carbon atoms in the ring system is/are hetero element(s) other than carbon, for example nitrogen, oxygen or sulfur.
- the ring system contains from 1 to 3 heteroatoms.
- Preferred ring sizes of rings of the ring system include about 5 to about 6 ring atoms; and such preferred ring sizes are also referred to as "lower”.
- heterocyclyl Encompassed by heterocyclyl are fused arylheterocyclyl and fused heteroarylheterocyclyl as defined herein when bonded through the heterocyclyl moiety thereof.
- the designation of the aza, oxa or thia as a prefix before heterocyclyl define that at least a nitrogen, oxygen or sulfur atom is present respectively as a ring atom.
- "Substituted heterocyclyl” means a heterocyclyl group as defined above which is substituted with one or more "ring group substituents" (preferably 1 to 3) which may be the same or different and are as defined herein.
- the nitrogen atom of an heterocyclyl may be a basic nitrogen atom.
- the nitrogen or sulfur atom of the heterocyclyl may also be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
- exemplary monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,3-dioxolanyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.
- substituted monocyclic azaheterocyclyl is substituted directly or through a linker by at least one substituent that is, or encompasses, or is substituted by an aromatic group as defined herein; for example aryl, heteroaryl, aryloxy, heteroaryloxy, aroyl or its thioxo analogue, heteroaroyl or its thioxo analogue, aroyloxy, heteroaroyloxy, aryloxycarbonyl, heteroaryloxycarbonyl, arylsulfonyl, heteroarylsulfonyl, arylsulfinyl, heteroarylsulfinyl, arylthio, heteroarylthio, aryldiazo, heteroaryldiazo.
- Preferred linkers include -C(O)-, -OC(O)-, lower alkyl, lower alkoxy, lower alkenyl, -O-, -S-, -C(O)C(O)-, -S(O)-, -S(O) 2 -, NR 80 -, where R 80 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or beteroaryl.
- Particularly preferred linkers are -C(O)- and -OC(O)-.
- Substituted multicyclic azaheterocyclyl means a multicyclic azaheterocyclyl group as defined above which is substituted with one or more "ring group substituents" (preferably 1 to 3) which may be the same or different and are as defined herein.”
- Substituted multicyclic azaheterocyclenyl means a multicyclic azaheterocyclenyl group as defined above which is substituted with one or more "ring group substituents" (preferably 1 to 3) which may be the same or different and are as defined herein.
- Heterocyclylene means a bivalent heterocyclyl group as defined herein having about 4 to about 8 carbon atoms. Preferred ring sizes of the heterocyclylene include about 5 to about 6 ring atoms; and such preferred ring sizes are also referred to as "lower”.
- the points of binding on the cycloalkylene group include 1,1-, 1,2-, 1,3-, or 1,4- binding patterns, and where applicable the stereochemical relationship of the points of binding is either cis or trans.
- Exemplary heterocyclylene groups include (1,1-, 1,2- or 1,3-)piperidinylene and (1,1- or 1,2-)tetrahydrofuranylene.
- “Substituted heterocyclylene” means a heterocyclylene group as defined above which is substituted with one or more "ring group substituents" (preferably 1 to 3) which may be the same or different and are as defined herein.
- Hydrophilate means a solvate wherein the solvent molecule(s) is/are H 2 O.
- Hydrolysis labile amine protecting group means an amine protecting group as defined herein which is readily removed by hydrogenation while remaining relatively stable to other reagents.
- a preferred hydrogenation labile amine protecting group is Cbz.
- Hydrophilicity labile acid protecting group means an acid protecting group as defined herein which is readily removed by hydrogenation while remaining relatively stable to other reagents.
- a preferred hydrogenation labile acid protecting group is benzyl.
- “Hygroscopicity” means sorption, implying an acquired amount or state of water sufficient to affect the physical or chemical properties of the substance (Eds. J. Swarbrick and J.C. Boylan, Encyclopedia of Pharmaceutical Technology, 10, 33).
- Iminic glycinimide derivative means an iminic Schiff base of a glycine that is useful in the synthesis of ⁇ -amino acids, both natural and unnatural.
- the iminic ester functionality may contain one or more asymmetric centers that may aid in stereoinduction during the bond formating process.
- these iminic glycinimide derivatives may be incorporated onto polymeric supports to facilitate combinatorial synthesis.
- Iminic glycinimide derivatives may be prepared by condensing a glycine ester with the appropropriate ketone in the presence of an acid catalyst. The reaction is facilitated by the removal of water.
- Iminic glycinimide derivatives are well known in the art for use in Michael Addition synthetic procedures, for example as disclosed by Guillena, G., et al., J. Org. Chem., 2000, 65, 7310-7322 , herein incorporated by reference.
- Particular examples of iminic glycinimide derivatives according to the invention include one selected from the group of formulae wherein:
- Peptidomimetic mean a polymer encompassing amino acid residues joined together through amide bonds.
- “Pharmaceutically acceptable ester” refers to esters that hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
- Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
- Exemplary esters include formates, acetates, propionates, butyrates, acrylates, ethylsuccinates, and the like.
- prodrugs refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
- prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. Functional groups that may be rapidly transformed, by metabolic cleavage, in vivo form a class of groups reactive with the carboxyl group of the compounds of this invention.
- alkanoyl such as acetyl, propanoyl, butanoyl, and the like
- unsubstituted and substituted aroyl such as benzoyl and substituted benzoyl
- alkoxycarbonyl such as ethoxycarbonyl
- trialkylsilyl such as trimethyl- and triethysilyl
- monoesters formed with dicarboxylic acids such as succinyl
- the compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group.
- a thorough discussion is provided in Design of Prodrugs, H. Bundgaard, ed., Elsevier (1985 ); Methods in Enzymology; K. Widder et al, Ed., Academic Press, 42, 309-396 (1985) ; A Textbook of Drug Design and Developement, Krogsgaard-Larsen and H. Bandaged, ed., Chapter 5 ; " Design and Applications of Prodrugs" 113-191(1991 ); Advanced Drug Delivery Reviews, H.
- “Pharmaceutically acceptable salts” refers to the relatively non-toxic, inorganic and organic acid addition salts, and base addition salts, of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds. In particular, acid addition salts can be prepared by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.
- Exemplary acid addition salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, sulphamates, malonates, salicylates, propionates, methylene-bis- ⁇ -hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinateslaurylsulphonate
- Base addition salts can also be prepared by separately reacting the purified compound in its acid form with a suitable organic or inorganic base and isolating the salt thus formed.
- Base addition salts include pharmaceutically acceptable metal and amine salts. Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminum salts. The sodium and potassium salts are preferred.
- Suitable inorganic base addition salts are prepared from metal bases which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide and the like.
- Suitable amine base addition salts are prepared from amines which have sufficient basicity to form a stable salt, and preferably include those amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use.
- Ammonia ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'- dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylanimonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, e.g., lysine and arginine, and dicyclohexylamine, and the like.
- Ring group substituents mean substituents attached to aromatic or non-aromatic ring systems inclusive of aryl, heteroaryl, hydroxy, alkoxy, cyclyloxy, aryloxy, heteroaryloxy, acyl or its thioxo analogue, cyclylcarbonyl or its thioxo analogue, aroyl or its thioxo analogue, heteroaroyl or its thioxo analogue, acyloxy, cyclylcarbonyloxy, aroyloxy, heteroaroyloxy, halo, nitro, cyano, carboxy (acid), -C(O)-NHOH, -C(O)-CH 2 OH, -C(O)-CH 2 SH, -C(O)-NH-CN, sulpho, phosphono, alkylsulphonylcarbamoyl, tetrazolyl, arylsulphonylcarbamoyl, N-me
- Acidic/amide ring group substituents are carboxy (acid), -C(O)-NHOH, C(O)-CH 2 OH- C(O)-CH 2 SH, -C(O)-NH-CN, sulpho, phosphono, alkylsulphonylcarbamoyl, tetrazolyl, arylsulphonylcarbamoyl, N-methoxycarbamoyl, heteroarylsulphonylcarbamoyl, 3-hydroxy-3-cyclobutene-1,2-dione, 3,5-dioxo-1,2,4-oxadiazolidinyl or hydroxyheteroaryl such as 3-hydroxyisoxazolyl, 3-hydoxy-1-methylpyrazoly and Y 1 Y 2
- Solvate means a physical association of a compound of this invention with one or more solvent molecules. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate” encompasses both solution- phase and isolable solvates. Exemplary solvates include hydrates, ethanolates, methanolates, and the like.
- Particular compounds according to the invention are compounds BW and CU.
- the compounds of the invention optionally are supplied as salts.
- Those salts that are pharmaceutically acceptable are of particular interest since they are useful in administering the foregoing compounds for medical purposes.
- Salts that are not pharmaceutically acceptable are useful in manufacturing processes, for isolation and purification purposes, and in some instances, for use in separating stereoisomeric forms of the compounds of this invention. The latter is particularly true of amine salts prepared from optically active amines.
- base addition salts may be formed and are simply a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free acid form.
- acid addition salts may be formed and are simply a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form.
- a preferred embodiment of the use of a compound according to the invention in a method is for treating a patient suffering from an HCV infection or physiological conditions related to the infection comprising administering to the patient a pharmaceutically effective amount of a compound BW or CU.
- Another preferred embodiment of the use of a compound according to the invention in a therapeutic method is for treating a patient suffering from an HCV infection or physiological conditions related to the infection comprising administering a pharmaceutically effective amount of a compound BW or CU in combination with a pharmaceutically effective amount of another anti-HCV therapeutic to the patient.
- Another object of the present invention is to provide pharmaceutical compositions comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity, including immunomodulatory compounds such as immunostimulatory cytokines exhibiting HCV antiviral activity, and a pharmaceutically acceptable carrier or diluent.
- kits or single packages combining two or more active ingredients useful in treating or preventing an HCV infection in a patient.
- a kit may provide (alone or in combination with a pharmaceutically acceptable diluent or carrier), the compound of BW or CU and the additional active ingredient (alone or in combination with diluent or carrier) other anti-HCV therapeutic.
- Compounds BW and CU may be prepared by the application or adaptation of known methods as used heretofore or described in the literature, or by methods according to this invention herein.
- Another object of the present invention is to provide medicaments useful in methods of treating or preventing a HCV infection in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a combination of one or more HCV serine protease inhibitors; one or more interferons exhibiting anti-HCV activity; and/or one or more compounds having anti-HCV activity, including immunomodulatory compounds such as immunostimulatory cytokines exhibiting HCV antiviral activity.
- Another object of the present invention is the use of one or more HCV serine protease inhibitors in combination with one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti-HCV activity, including immunomodulatory compounds such as immunostimulatory cytokines exhibiting HCV antiviral activity, to prepare a medicament for treating or preventing a HCV infection in a patient in need thereof.
- immunomodulatory compounds such as immunostimulatory cytokines exhibiting HCV antiviral activity
- a further object of the present invention is a kit or pharmaceutical pack for treating or preventing HCV infection in a patient, wherein the kit or pharmaceutical pack comprises a plurality of separate containers, wherein at least one of said containers contains one or more HCV serine protease inhibitors, at least another of said containers contains one or more interferons or compounds that induce the production of an inteferon that exhibit anti-HCV activity (alone or in combination with a pharmaceutically acceptable carrier or diluent), and, optionally, at least another of said containers contains one or more compounds having anti-HCV activity (alone or in combination with a pharmaceutically acceptable carrier or diluent), including immunomodulatory compounds such as immunostimulatory cytokines exhibiting HCV antiviral activity.
- the kit or pharmaceutical pack comprises a plurality of separate containers, wherein at least one of said containers contains one or more HCV serine protease inhibitors, at least another of said containers contains one or more interferons or compounds that induce the production of an inteferon that exhibit anti-
- Yet another object of the present invention is to provide medicaments useful in a method of inhibiting hepatitis C virus replication in a cell, comprising contacting said cell, a hepatitis C virus serine protease inhibitor, and optionally an interferon or compounds that induce the production of an interferon that have anti-hepatitis C virus activity.
- the amount of the HCV serine protease inhibitor(s), interferon(s), or anti-HCV compound(s) in any of the foregoing applications can be a pharmaceutically effective amount, a suboptimal anti-HCV effective amount, or combinations thereof, so long as the final combination of HCV protease inhibitor(s), interferon(s), and/or anti-HCV compound(s) comprises a pharmaceutically effective amount of compounds that is effective in treating or preventing HCV infection in a patient.
- the starting materials and intermediates of compounds of the invention may be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.
- a compound of formula 1 wherein the variables and moiety thereof are as described herein may be prepared by treating a compound of formula 2, wherein the variables and moiety thereof are as described herein, with an appropriate oxidizing agent and under appropriate conditions.
- a particular oxidizing agent is DMP reagent.
- Particular conditions include carrying out the oxidation in an appropriate organic solvent such as dichloromethane at about room temperature.
- R 0 is a bond of difluoromethylene
- R 1 is hydrogen, optionally substituted aliphatic group, optionally substituted cyclic group or optionally substituted aromatic group
- R 2 and R 9 are each independently optionally substituted aliphatic group, optionally substituted cyclic group or optionally substituted aromatic group
- R 3 , R 5 and R 7 are each independently (optionally substituted aliphatic group, optionally substituted cyclic group or optionally substituted aromatic group) (optionally substituted methylene or optionally substituted ethylene), optionally substituted (1,1- or 1,2-)cycloalkylene or optionally substituted (1,1- or 1,2-)heterocyclylene
- R 4 , R 6 , R 8 and R 10 are each independently hydrogen or optionally substituted aliphatic group; is substituted monocyclic azaheterocyclyl or optionally substituted multicyclic azaheterocyclyl, or optionally substituted multicyclic azaheterocyclyl
- This invention also provides a compound having the structural formula: wherein:
- a particular embodiment according to the invention is where R 0 is a bond.
- R 0 is difluoromethylene
- R 1 is hydrogen or optionally substituted lower aliphatic group.
- R 1 is hydrogen or lower alkyl.
- a preferred embodiment according to the invention is where R 1 is hydrogen.
- R 2 is optionally substituted lower aliphatic group or optionally substituted monocyclic group.
- R 2 is carboxymethyl, 1-carboxy-2-phenylethyl, cyclopropyl, cyclobutyl, 1-cyclohexylethyl, 1-phenylethyl, but-2-yl, 1-pyrid-4-ylethyl, propen-3-yl or methylbut-2-yl; more preferred cyclopropyl.
- a particular embodiment according to the invention is where R 3 is optionally substituted lower aliphatic group methylene.
- R 3 is optionally halo substituted lower (alkyl or alkenyl)methylene.
- R 3 is propylmethylene, 2,2-difluoroethylmethylene, 2,2,2-trifluoromethylene or propen-3-ylmethylene; more preferred R 3 is propylmethylene or 2,2-difluoroethylmethylene further preferred R 3 is propylmethylene.
- R 4 is hydrogen or optionally substituted lower aliphatic group.
- R 4 is hydrogen or lower alkyl.
- a preferred embodiment according to the invention is where R 4 is hydrogen.
- a particular embodiment according to the invention is where R 5 is optionally substituted lower aliphatic group methylene.
- R 5 is optionally (phenyl, carboxy, carboxamido or alkoxycarbonyl) substituted lower (alkyl or alkenyl) methylene.
- R 5 is methylmethylene, isopropylmethylene, t -butylmethylene, but-2-ylmethylene, butylmethylene, benzylmethylene, 3-methylbutylmethylene, 2-methylpropyl-methylene, carboxymethylmethylene, carboxamidomethylmethylene, benzyloxycarbonylmethylmethylene, benzyloxycarbonylpropylmethylene, or phenylpropen-3-ylmethylene; more preferred R 5 is isopropylmethylene or t -butylmethylene.
- R 6 is hydrogen or optionally substituted lower aliphatic group.
- R 6 is hydrogen or lower alkyl.
- a preferred embodiment according to the invention is where R 6 is hydrogen.
- R 7 is optionally substituted lower aliphatic group methylene, optionally substituted lower cyclic group methylene or optionally substituted monocyclic (aryl or heteroaryl) methylene.
- R 7 is optionally substituted lower alkylmethylene, optionally substituted lower cycloalkylmethylene or optional substituted phenylmethylene.
- R 7 is methylmethylene, isopropylmethylene, n-propylmethylene, phenylmethylene, cyclohexylmethylene, cyclopentylmethylene, t-butylmethylene, s-butylmethylene, cyclohexylmethylmethylene, or phenylmethylmethylene, more preferred is isopropylmethylene, cyclohexylmethylene, cyclopentylmethylene, t-butylmethylene or s-butylmethylene.
- a preferred embodiment according to the invention is also wherein each of R 3 , R 5 and R 7 is mono substituted methylene.
- a preferred embodiment according to the invention is also wherein R 3 is mono substituted methylene and has an (S) configuration on the carbon attached to the -C(O)-R 0 -C(O)-NR 1 R 2 moiety.
- R 8 is hydrogen or optionally substituted lower aliphatic group.
- R 8 is hydrogen or lower alkyl.
- a preferred embodiment according to the invention is where R 8 is hydrogen.
- R 9 is optionally substituted lower aliphatic group or optionally substituted monocyclic aromatic group.
- R 9 is optionally substituted lower alkyl or optionally substituted monocyclic heteroaryl.
- R 9 is optionally (carboxy, (loweralkyl)SO 2 NH-, (lower alkyl)HNCO-, hydroxy, phenyl, heteroaryl, or (lower alkyl)OC(O)NH-)-substituted lower alkyl, or optionally substituted monocyclic heteroaryl.
- R 9 is lower alkyl substituted by (mono- or di-)MeOC(O)NH-; more preferred is 1,2-di(MeOC(O)NH)ethyl or 1-(MeOC(O)NH)ethyl.
- R 9 is (carboxy, (lower alkyl)HNCO- or tetrazolyl)substituted lower alkyl; more preferred 3-carboxypropyl, 2-tetrazol5ylpropyl, 3-(N-methylcarboxamido)propyl or 3-carboxy-2,2-dimethylpropyl; further preferred is 3-carboxypropyl, 2-tetrazol-5ylpropyl or 3-(N-methylcarboxamido)propyl.
- R 9 is optionally substituted lower alkyl; more preferred is 1-hydroxy-2-phenylethyl, methyl, isopropyl or t-butyl; further preferred is methyl, isopropyl or t-butyl.
- R 9 is selected from the group consisting of
- R 9 is pyrazinyl.
- R 10 is hydrogen or optionally substituted lower aliphatic group.
- R 10 is hydrogen or lower alkyl.
- a preferred embodiment according to the invention is where R 10 is hydrogen.
- a preferred embodiment according to the invention is where as a substituted monocyclic azaheterocyclyl is substituted pyrrolidinyl.
- a preferred embodiment according to the invention is where as a substituted monocyclic azaheterocyclyl is optionally substituted or optionally substituted wherein Ar is R 2 that comprises an aromatic moiety; more preferred is optionally substituted further preferred is optionally substituted
- Another preferred embodiment according to the invention is where as an optionally substituted multicyclic azaheterocyclyl is optionally substituted more preferred is optionally substituted Particular substituents for are hydroxy, fluoro or oxo.
- Another preferred embodiment according to the invention is where as an optionally substituted multicyclic azaheterocyclenyl is optionally substituted more preferred is further preferred is
- Another preferred embodiment according to the invention is where as an optionally substituted multicyclic azaheterocyclenyl is optionally substituted
- a preferred embodiment according to the invention is where the -C(O)-N(R 4 )-R 3 -C(O)R 0 C(O)NR 2 R 1 moiety attached to is attached a carbon ⁇ to the nitrogen atom.
- a preferred embodiment according to the invention is where L is -C(O)- or - OC(O)-.
- a preferred embodiment according to the invention is where n is 0.
- n 1
- a preferred embodiment according to the invention is where R 11 is -CO 2 R 13 .
- R 12 is
- R 13 is an optionally substituted aliphatic group.
- R 13 is an alkyl group.
- a preferred embodiment according to the invention is where R 13 is lower alkyl.
- R 13 is methyl
- a preferred embodiment according to the invention is where R 14 is -CO 2 R 16 .
- a particular embodiment according to the invention is where R 15 is alkyl.
- a preferred embodiment according to the invention is where R 15 is lower alkyl.
- a preferred embodiment according to the invention is where R 15 is methyl.
- a particular embodiment according to the invention is where R 16 is optionally substituted aliphatic.
- R 16 is alkyl
- a preferred embodiment according to the invention is where R 16 is lower alkyl.
- a preferred embodiment according to the invention is where R 16 is t-Bu.
- a particular embodiment according to the invention is where R 17 is optionally substituted aryl.
- a preferred embodiment according to the invention is where R 17 is phenyl.
- a particular embodiment according to the invention is where R 18 is optionally substituted aryl.
- a preferred embodiment according to the invention is where R 18 is phenyl.
- a particular embodiment according to the invention is where p 0 is selected from the group consisting of BOC, CBz and -CO 2 alkyl.
- a preferred embodiment according to the invention is where p 0 is BOC.
- a compound of formula 2, wherein the variables and moiety thereof are as described herein may be prepared by coupling a compound of formula 3, wherein the variables and moiety thereof are as described herein, and a compound of formula 4, wherein the variables thereof are as described herein, with an appropriate coupling agent and under appropriate conditions.
- Particular coupling agent and conditions include using DIC and HOAt in an appropriate organic solvent such as DMF at about 0°C or using PyBop and DIPEA in an appropriate organic solvent such as dichloromethane at about room temperature.
- a compound of formula 3, wherein the variables and moiety thereof are as described herein, may be prepared by coupling a compound of formula 5, wherein the variables thereof are as described herein, and a compound of formula 6, wherein P 2 is an acid protecting group and the moiety thereof is as described herein, with an appropriate coupling agent and under appropriate coupling conditions, followed by an appropriate deprotecting agent and under appropriate deprotecting conditions.
- Particular coupling agent and conditions include using DIC or DCC and HOAt in an appropriate organic solvent such as DMF or dichloromethane at about 0°C to about room temperature.
- the deprotecting is carried out using an appropriate deprotecting agent that depends on the nature of the protecting agent, i.e., whether it is removable (labile) under acid, base, or hydrogenation conditions, and other reactive moieties in the compound undergoing deprotection, i.e., a deprotecting agent is chosen to carry out the deprotection without effecting the other reactive moieties unless a concomitant reaction is desired.
- a particular acid protecting agent is C 1 to C 8 lower alkyl; more particular methyl.
- a particular deprotecting agent is an inorganic base such as an alkali hydroxide; more particular NaOH.
- Particular deprotection conditions encompass carrying out the deprotection in an alcoholic solvent such as methanol or ethanol at about room temperature.
- a compound of formula 5, wherein n is 0 and the other variables are as described herein, i.e., compound 5a, may be prepared by deprotecting a compound of formula 7, wherein P 2 is an acid protecting group and the other variables thereof are as described herein, with an appropriate deprotecting agent and under appropriate conditions.
- the deprotecting is carried out using an appropriate deprotecting agent that depends on the nature of the protecting agent, i.e., whether it is removable (labile) under acid, base, or hydrogenation conditions, and other reactive moieties in the compound undergoing deprotection, i.e., a deprotecting agent is chosen to carry out the deprotection without effecting the other reactive moieties unless a concomitant reaction is desired.
- a particular acid protecting agent is C 1 to C 8 lower alkyl; more particular methyl.
- a particular deprotecting agent is an inorganic base such as an alkali hydroxide; more particular NaOH.
- Particular deprotection conditions encompass carrying out the deprotection in an alcoholic solvent such as methanol or ethanol at about room temperature.
- a compound of formula 7, wherein the variables thereof are as described herein, may be prepared by acylating a compound of formula 8, wherein the variables thereof are as described herein, with a compound of formula 9, wherein M is a displaceable moiety and the other variables thereof are as described herein, under appropriate conditions.
- Particular coupling conditions use DIC or DCC and HOAt in an appropriate organic solvent such as DMF or dichloromethane at about 0°C to about room temperature, or PyBop and DIPEA in an appropriate organic solvent such as DMF or dichloromethane at about room temperature; and preferably the latter conditions.
- a particular L is carbonyl.
- a particular M is hydroxy or N-oxysuccinimide.
- a compound of formula 5, wherein n is 1 and the other variables are as described herein, i.e. compound 5b, may be prepared by deprotecting a compound of formula 10, wherein P 2 is an acid protecting group and the other variables thereof are as described herein, with an appropriate deprotecting agent and under appropriate conditions.
- the deprotecting is carried out using an appropriate deprotecting agent that depends on the nature of the acid protecting agent, i.e., whether it is removable (labile) under acid, base, or hydrogenation conditions, and other reactive moieties in the compound undergoing deprotection, i.e., a deprotecting agent is chosen to carry out the deprotection without effecting the other reactive moieties unless a concomitant reaction is desired.
- a particular acid protecting agent is C 1 to C 8 lower alkyl; more particular methyl.
- a particular deprotecting agent is an inorganic base such as an alkali hydroxide; more particular NaOH.
- Particular deprotection conditions encompass carrying out the deprotection in an alcoholic solvent such as methanol or ethanol at about room temperature.
- a compound of formula 10, wherein the variables thereof are as described herein, may be prepared by acylating a compound of formula 11, wherein the variables thereof are as described herein, with a compound of formula 9, wherein the variables thereof are as described herein, under appropriate conditions.
- Particular coupling conditions use DIC or DCC and HOAt in an appropriate organic solvent such as DMF or dichloromethane at about 0°C to about room temperature, or PyBop and DIPEA in an appropriate organic solvent such as DMF or dichloromethane at about room temperature; and preferably the latter conditions.
- a particular L is carbonyl.
- a particular M is hydroxy or N-oxysuccinimide.
- a compound of formula 11, wherein the variables are as described herein, may be prepared by deprotecting a compound of formula 12, wherein P 1 is an amine protecting group and the other variables thereof are as described herein, with an appropriate deprotecting agent and under appropriate conditions.
- the deprotecting is carried out using an appropriate deprotecting agent that depends on the nature of the amine protecting agent, i.e., whether it is removable (labile) under acid, base, or hydrogenation conditions, and other reactive moieties in the compound undergoing deprotection, i.e., a deprotecting agent is chosen to carry out the deprotection without effecting the other reactive moieties unless a concomitant reaction is desired.
- a particular amine protecting agent is Cbz or BOC; more particular Cbz.
- a particular deprotecting agent is acid such as HCl or H 2 /Pd(OH) 2 ; more particular H 2 /Pd(OH) 2 .
- Particular deprotection conditions encompass carrying out the deprotection in an alcoholic solvent such as methanol or ethanol or an alkyl alkanoate solvent such as ethyl acetate at about room temperature.
- a compound of formula 12, wherein the variables thereof are as described herein, may be prepared by coupling a compound of formula 13, wherein the variables thereof are as described herein, with a compound of formula 14, wherein the variables thereof are as described herein, under appropriate conditions.
- Particular coupling conditions use HOAt/DIC and DIPEA in an appropriate organic solvent such as THF at about room temperature.
- a compound of formula 4, wherein the variables are as described herein, may be prepared by deprotecting a compound of formula 15, wherein the variables thereof are as described herein, with an appropriate deprotecting agent and under appropriate conditions.
- the deprotecting is carried out using an appropriate deprotecting agent that depends on the nature of the amine protecting agent, i.e., whether it is removable (labile) under acid, base, or hydrogenation conditions, and other reactive moieties in the compound undergoing deprotection, i.e., a deprotecting agent is chosen to carry out the deprotection without effecting the other reactive moieties unless a concomitant reaction is desired.
- a particular amine protecting agent is Cbz or BOC; more particular Cbz.
- a particular deprotecting agent is an acid such as HCl or H 2 /Pd(OH) 2 ; more particular H 2 /Pd(OH) 2 .
- Particular deprotection conditions encompass carrying out the deprotection in an alcoholic solvent such as methanol or ethanol or an alkyl alkanoate solvent such as ethyl acetate at about room temperature.
- a compound of formula 15, wherein the variables thereof are as described herein, may be prepared by coupling a compound of formula 16, wherein the variables thereof are as described herein, with a compound of formula 17, wherein the variables thereof are as described herein, under appropriate conditions.
- a particular amine protecting agent is Cbz or BOC; more particular Cbz.
- Particular coupling conditions use HOBT, PyBop and DIPEA in an appropriate organic solvent such as dichloromethane at about 0°C to about room temperature.
- a compound of formula 16, wherein the variables are as described herein may be prepared by deprotecting a compound of formula 18, wherein the other variables thereof are as described herein, with an appropriate deprotecting agent and under appropriate conditions.
- the deprotecting is carried out using an appropriate deprotecting agent that depends on the nature of the acid protecting agent, i.e., whether it is removable (labile) under acid, base, or hydrogenation conditions, and other reactive moieties in the compound undergoing deprotection, i.e., a deprotecting agent is chosen to carry out the deprotection without effecting the other reactive moieties unless a concomitant reaction is desired.
- a particular amine protecting agent is Cbz.
- a particular acid protecting agent is C 1 to C 8 lower alkyl; more particular methyl.
- a particular deprotecting agent is an inorganic base such as an alkali hydroxide; more particular NaOH.
- Particular deprotection conditions encompass carrying out the deprotection in an alcoholic solvent such as methanol or
- a compound of formula 18, wherein R 0 is a bond and the other variables thereof are as described herein, may be prepared by protecting a compound of formula 20, wherein the variables thereof are as described herein, with a compound of formula 19, wherein the variables thereof are as described herein, under appropriate conditions.
- a particular amine protecting agent is Cbz or BOC.
- Particular coupling conditions use an appropriate organic solvent such as dichloromethane at about 0°C to about room temperature.
- a compound of formula 20, wherein R 4 is hydrogen and the other variables are as described herein, may be prepared by hydrogenating a compound of formula 21, wherein the variables thereof are as described herein, with an appropriate hydrogenating agent and under appropriate conditions.
- a particular hydrogenating agent is H 2 /Pd(OH) 2 .
- Particular hydrogenating conditions encompass carrying out the hydrogenation in an alcoholic solvent such as methanol or ethanol or an alkyl alkanoate solvent such as ethyl acetate at about room temperature.
- a compound of formula 20 wherein R 4 is optionally substituted aliphatic and the other variables are as described herein may be prepared by alkylating compound 20' wherein the variables are as described herein with compound 22 (alkylating agent) wherein R 4 is optionally substituted aliphatic and Q is a displaceable group such as a halides, tosylates or sulfonates, under appropriate conditions.
- alkylating agents include aliphatic (halides, tosylates or sulfonates).
- Appropriate alkylating conditions encompass carrying out to alkylation in an appropriate organic solvent such as an alcoholic solvent, e.g., methanol or ethanol, or enteric solvent, e.g., ether or tetrahydrofuran at about room temperature to about reflux.
- an appropriate organic solvent such as an alcoholic solvent, e.g., methanol or ethanol, or enteric solvent, e.g., ether or tetrahydrofuran at about room temperature to about reflux.
- a compound of formula 21, wherein the variables are as described herein, may be prepared by alkylating a compound of formula 22, wherein the variable thereof is as described herein, with a compound of formula 23, wherein the R 3' s independently are optionally substituted aliphatic group, optionally substituted cyclic group or optionally substituted aromatic group as described herein, under appropriate conditions.
- Particular alkylating conditions encompass carrying out the alkylation using a strong base such as potassium t- butoxide in an alcoholic solvent such as methanol or ethanol at about room temperature.
- a compound of formula 24 wherein the variables thereof are as described herein may be prepared by effecting a Michael addition on a Michael acceptor of formula 29, wherein the variable thereof is as described herein, with an iminic glycinimide derivative.
- Michael additions comprise appropriate aprotic polar solvents, alkali methyl hydroxide bases, and appropriate temperatures.
- aprotic polar solvents include DCM, ACN, or THF depending on the reaction conditions.
- Appropriate bases include CsOH, NaOH, KOH, and LiOH.
- Appropriate temperatures range from about -78°C to about 0°C, more particularly at about -60°C.
- Iminic glycinimides useful in the invention are described herein.
- a preferred iminic glycinimide is N-(diphenylmethylene)glycine tert-butyl ester.
- Michael addition conditions may be affected with or without a phase transfer catalyst (PTC) (chiral and nonchiral).
- PTC phase transfer catalyst
- a preferred PTC is O -[9] allyl- N -9-anthracenylmethylcinchonidium bromide.
- a compound of formula 25, wherein the variables thereof are as described herein, may be prepared by imine cleavage and cyclizing of the compound of formula 24.
- Cleavage and cyclizing conditions include the use of polar solvents, acid reagents, and temperatures of about room temperature to about 150°C. Preferred conditions include the use of EtOH, AcONa and NH 2 OH.HCl, and a temperature of about boiling point for the solvent used.
- a compound of formula 26, wherein the variables thereof are as described herein, may be prepared by protecting the amide of the compound of formula 25, wherein the variables thereof are as described herein, with a suitable amide protecting group such as BOC.
- suitable protecting groups include CBz, -CO 2 alkyl.
- Protecting conditions include the use of aprotic polar solvents, organic bases as catalysts, and temperatures of about 0°C-100°C.
- Preferred conditions include the use of ACN, dimethyl amino pyridine, and a temperature of about room temperature.
- a compound of formula 27, wherein the variables thereof are as described herein, may be prepared by reducing the protected compound of formula 26, wherein the variables thereof are as described herein. Two reductions are, in fact, done. The first reduction is of the amide to a hemiaminal using DIBALH or superhydride [LiBEtH]. The second reduction is of the hemiaminal to the amine using Et 3 SiH and BF 3 •OEt 2 . See Collado, I; Ezquerra, J.; Mateo, A.I.; Rubio, A., J. Org. Chem.
- a compound of formula 28, wherein the variables thereof are as described herein, may be prepared by deprotecting the compound of formula 27, wherein the variables thereof are as described herein. See Gibson, F.G.; Bermeier, S.C.; Rapoport, H., J. Org Chem. 1994, 59, 3216-3218 for the conditions for selective removal of N-BOC protecting group in the presence of tert-butyl ester.
- the deprotecting conditions will be dependent upon the choice of the protecting group.
- CBz hydrogenation or basic conditions may be used.
- BOC 1 N HCl in ethyl acetate may be used. See, Greene, T.W.; P.G.M. in Protective Groups in Organic Synthesis, Wiley, New York, 1991 .
- a compound of formula 3 may be prepared by coupling a compound of formula 5 with a compound of formula 28 under conditions described above herein.
- Methods for preparing R 3 , R 5 or R 7 as optionally substituted ethanediyl moieties include those known to those skilled in the art, e.g., those methods described in The organic Chemistry of ⁇ -Lactams" edited by G. Georg, VCH Publishers, Inc. (1993), e.g., pages 240-241 and 303-20 305 .
- a peracid for example peracetic acid in acetic acid or m-chloroperoxybenzoic acid in an inert solvent such as dichloromethane
- a compound that is prepared as described herein may be recovered from the reaction mixture by conventional means.
- the compounds may be recovered by distilling off the solvent from the reaction mixture or, if necessary after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract.
- the product can, if desired, be further purified by various well techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography.
- compounds of the invention may be prepared by interconversion of other compounds of the invention.
- compounds of formula 1 containing sulphoxide linkages may be prepared by the oxidation of corresponding compounds containing S-linkages.
- the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g., 3-chloroperbenzoic acid, preferably in an inert solvent, e.g., dichloromethane, preferably at or near room temperature, or alternatively by means of potassium hydrogen peroxomonosulphate in a medium such as aqueous methanol, buffered to about pH 5. at temperatures between about 0°C and room temperature. This latter method is preferred for compounds containing an acid-labile group.
- compounds of formula 1 containing sulphone linkages may be prepared by the oxidation of corresponding compounds containing -S- or sulphoxide linkages.
- the oxidation may conveniently be carried out by means of reaction with a peroxyacid, e.g., 3-chloroperbenzoic acid, preferably in an inert solvent, e.g., dichloromethane, preferably at or near room temperature.
- compounds of the present invention may contain asymmetric centers. These asymmetric centers may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds according to the invention. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallization techniques, or they are separately prepared from the appropriate isomers of their intermediates.
- tautermeric forms are included in the recitation of a given group, e.g., thioxo/mercapto or oxo/hydroxyl.
- Acid additional salts are formed with the compounds of the invention in which a basic function such as an amino, alkylamino, or dialkylamino group is present.
- the pharmaceutically acceptable, i.e., nontoxic, acid addition salts are preferred.
- the salts chosen are chosen optimally to be compatible with the customary pharmaceutical vehicles and adapted for oral or parenteral administration.
- Acid addition salts of the compounds of this invention may be prepared by reaction of the free base with the appropriate acid, by the application or adaptation of known methods.
- the acid addition salts of the compounds of this invention may be prepared either by dissolving the free base in water or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
- acids for use in the preparation of such salts are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, various organic carboxylic and sulfonic acids, such as acetic acid, citric acid, propionic acid, succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid, malic acid, methanesulfonic acid, toluenesulfonic acid, fatty acids, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, cyclopentanepropionate, digluconate, dodecylsulfate, bisulfate, butyrate, lactate, laurate, lauryl sulfate, malate, hydroiodide, 2-hydroxy-ethanesulfonate, glycerophosphate, picrate, pivalate, pamoate, pectinate, persulfate, 3-
- the acid addition salts of the compounds of this invention can be regenerated from the salts by the application or adaptation of known methods.
- parent compounds of the invention can be regenerated from their acid addition salts by treatment with an alkali, e.g., aqueous sodium bicarbonate solution or aqueous ammonia solution.
- parent compounds of the invention can be regenerated from their base addition salts by the application or adaptation of known methods.
- parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e.g., hydrochloric acid.
- Base addition salts may be formed where the compound of the invention contains a carboxy group, or a sufficiently acidic bioisostere.
- the bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the cations.
- Pharmaceutically acceptable salts including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylaminonium hydroxide, and the like.
- Hydrates of compounds of the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g., hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol.
- the starting materials and intermediates may be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.
- the starting material compound clxxxxi (94 mg, 0.14 mmole) is dissolved in a mixture of THF (10 mL) and DCM (20 mL). The DMP reagent (118 mg, 0.28 mmol) is then added. After stirring at room temperature for 2 hours. The reaction is dumped in a separatory funnel containing Dri Solv THF (120 mL). The reaction is washed with 10% Na 2 SO 3 (50 mL), and then brine (75 mL). The organic layer is then separated, dried over MgSO 4 and the solvent removed under reduced pressure. After chromatography (silica gel: elution with 50% Dri Solv THF/EtOAc, and then 4% MeOH/THF). Fractions are checked by MS. Appropriate fractions are lyopholized to yield compound DZ (38.8 mg, 41%).
- the starting compound clxxxxv (185 mg, 0.26mmol) is dissolved in THF (20 mL).
- the DMP reagent (219 mg, 0.52 mmol) is then added. After stirring at room temperature for 1 hour. TLC shows complete conversion to ketone (5% MeOH/THF).
- the reaction is dumped in a separatory funnel containing Dri Solv THF (120 mL). The reaction is washed with 10% Na 2 SO 3 (50 mL), and then brine (75 mL).
- the xanthate compound iii ( ⁇ 13.4 mmol) is dissolved in toluene (100 mL). To this solution is added AIBN (216 mg, 1.34 mmol). The resulting solution is degassed with dry nitrogen and then treated with n-Bu 3 SnH (5.4 mL, 20.1 mmol). The reaction mixture is heated at 90 °C for 3 hours. At this point, the reaction is cooled to room temperature and concentrated in vacuo. The resulting residue is purified with silica gel chromatography (15-20% EtOAc/Hexanes) to provide 2.8 g (66% overall from compound ii) of compound iv,
- Methyl 5-cyanopentanoate (4.8 g, 34 mmol) is dissolved in toluene, triethylammonium chloride (14 g, 102 mmol) and sodium azide (6.63, 102 mmol) is added. The mixture is heated to reflux for overnight. The reaction mixture is cooled to room temperature, water is added to extract (3x100 mL) methyl 5-tetrazol-5-ylpentanoate from the organic. To the aqueous phase, concentrate HCl is added to adjust pH to 2. The product is extracted from the aqueous solution with EtOAc (3x50 mL). The organic is combined, dried and concentrated to yield 4.25 g (68%) of methyl 5-tetrazol-5-ylpentanoate.
- Methyl 5-tetrazol-5-ylpentanoate (4.23 g, 23 mmol) and trichioroacetic acid (8.69 g, 53 mmol) are dissolved in 50 mL of CHCl 3 ⁇ -Methylstyrene (2.72, 23 mmol) is added to the solution dropwise, and the reaction mixture is allowed to stirred at about room temperature for overnight.
- the reaction mixture is diluted with EtOAc to 200 mL, and organic layer is washed with 10% aqueous KOH and brine. The organic layer is dried, concentrated.
- the product is purified by flash column chromatography to yield 6.6 g (95%) methyl 5-[N-(1,1-dimethylbenzyl)tetrazol-5-yl]pentanoate.
- Methyl 5-[N-(1,1-dimethylbenzyl)tetrazol-5-yl]pentanoate (6.6 g, 21.8 minol) is dissolved in methanol (100 mL) and 23 mL of 1 N aqueous NaOH is added. The mixture is stirred overnight and is concentrated to remove methanol. The residue is dissolved in water (100 mL) and the solution is neutralized by adding the same equivalent of 1 N aqueous HCl. The product is extracted with EtOAc (3x50 mL). The organic is dried and concentrated to yield 4.75g (75%) 5-[N-(1,1-dimethylbenzyl)tetrazol-5-yl]pentanoic acid.
- the reaction is quenched by pouring the mixture into a water/ether mixture (1:1) and then the layers are allowed to separate. The aqueous layer is further extracted by ether twice. All organic layers is washed by water, brine and dried over MgSO 4 before being concentrated to a yellow oil.
- the desired compound ii"' is isolated by silica gel chromatography (EtOAc/Hexanes 2/1) in 83%
- N-pyrazin-2-ylcarbonyl-Val-Val-4-(TIQ carbonyloxy)-Pro methyl ester (5.27 g, 81.7%).
- N-Boc-L- tert -Leucine (2.3 g, 10 mmol) and L- tert -Leucine methyl ester hydrochloride (2 g, 11 mmol) are combined in DMF (30 mL).
- HOAt 1.6 g, 11.5 mmol
- the resulting mixture is stirred for 20 minutes under N 2 and then lowered to 0°C whereupon DIC (1.8 mL, 11.5 mmol) and 2,4,6-collidine (1.45 mL, 11 mmol) are added.
- the resulting solution is stirred overnight with warming to room temperature.
- reaction mixture is diluted with EtOAc, and the organic phase washed with 1 N HCl, saturated NaHCO 3 and brine. Following the concentration of the organic phase, the resultant residue is chromatographically purified by 20% - 30% EtOAc/hexanes gradient to yield compound cv (3.3 g, 92%).
- reaction mixture is stirred at room temperature overnight. At this point, the reaction mixture is filtered through celite. The filtrate is diluted with EtOAc (120 mL) and washed with water and brine. The organic phase is dried and concentrated to a yellow oil that is purified by silica gel chromatography (50% EtOAc/hexanes) to yield compound cxvi (0.714 g, 66%).
- N-Cbz-L-Valine (6.28 g, 25 mmol) is dissolved in DCM (30 mL).
- HOBT (3.38 g, 25 mmol) and DCC (25 mL, 1 M solution) are added to this solution and stirred five minutes.
- L-tert Leucine methyl ester hydrochloride (25 mL, 1 M solution) is added to this mixture and stirred overnight under N 2 .
- the reaction mixture is diluted with EtOAc, washed with 1 N HCl, saturated NaHCO 3 and brine.
- the organic phase is dried over Na 2 SO 4 , a filtered and concentrated.
- the residue is chromatographically purified by 20%-30% EtOAc/hexanes to yield compound xx (2.96g, 31%).
- reaction mixture is diluted with EtOAc, and the organic phase is washed with saturated NaHCO 3 and brine. Following the concentration of the organic phase, the residue is chromatographically purified by 30%-40% EtOAc/Hexanes to yield compound xxi (2.07g, 75.8%).
- Boc-NVA-OH (24.96 g, 114.9 mmol) is dissolved in THF (200 mL).
- CD1 22.35, 137.8 mmol is added portion-wise to the solution, and the solution is stirred for 30 minutes.
- N,O-Dimethylhydroxylamine hydrochloride (12.33 g, 126.4 mmol) is dissolved in DMF (50 mL) and then DIPEA (22 mL, 126.4 mmol) is added to the solution.
- the DMF solution is allowed to stir at room temperature for 20 minutes and then added to THF solution.
- the resulting mixture is stirred over a weekend under N 2 .
- the reaction mixture is concentrated in vacuo to 100 mL total volume. This organic phase is washed with 1 N HCl, saturated NaHCO 3 and brine. The organic phase is concentrated to yield crude compound cxxi (25.3 g).
- N-Cbz-L-Cyclohexylglycine (3 g, 10.3 mmol) is dissolved in DCM (36 mL). HOAt (1.5 g, 11.28 mmol) and DCC (11.28 mL, 11.28 mmol) are added to this solution and stirred five minutes. L-tert-Leucine methyl ester hydrochloride (103 mL, 1 M solution, 10.3 mmol) is added to this mixture and stirred overnight under N 2 . The reaction mixture is filtered through celite, rinsed with EtOAc and concentrated to a residue that is purified chromatographically using 20% - 30% EtOAc/hexanes to yield compound cxxvii (2.2 g, 52%).
- reaction mixture After stirring over 2 days at room temperature, the reaction mixture is filtered through Celite, and concentrated to a residue that is purified by column chromatography (50% EtOAc/hexanes) to yield compound cxxxiv as a white solid (1.06 g, 83%).
- a solution of compound cxxxxviii (0.366 g, 0.718 mmol) in DCM is cooled in an ice bath and treated with PyBop (0.599 g, 1.15 mmol). After stirring at room temperature for 0.5 hour, the mixture is cooled by an ice bath and treated with a solution of compound xiii' (0.200 g, 1.08 mmol) in THF and DIPEA (0.250 mL, 1.44 mmol). The mixture is stirred at room temperature overnight and then quenched with NH 4 Cl solution. The solvent is concentrated and the mixture is dissolved in EtOAc (100 mL).
- a DCM solution (10 mL) of the crude compound cli (516 mg, 1.61 mmol) is treated with HOBT (436 mg, 3 mmol) and DIC (0.328 mL. 2.09 mmol). After stirring at room temperature for 30 minutes, the reaction mixture is treated with a DCM solution (5 mL) containing glycine benzylester-TsOH salt (815 mg, 2.42 mmol) and DIPEA (0.422 mL, 2.42 mmol). After stirring at room temperature for 12 hours, the reaction mixture is quenched with water and extracted with EtOAc.
- a DCM solution (4 mL) of the HCl salt of compound vii (96 mg, 0.144 mmol) is treated with PyBOP (120 mg, 0.23 mmol) and DIPEA (0.1 mL, 0.576 mmol). After stirring at room temperature for 30 minutes, the solution is treated with a THF solution (4 mL) containing compound clv (0.288 mmol) and DIPEA (0.2 mL, 1.152 mmol). The reaction mixture is stirred at room temperature overnight. The reaction mixture is then diluted with EtOAc (50 mL), and the organic phase then washed with NaHCO 3 and brine. The organic phase is concentrated in vacuo and the residue purified by silica gel chromatography (80% EtOAc/hexanes) to yield compound clx (113 mg, 89%).
- a DCM solution (6 mL) of compound vii (140 mg, 0.235 mmol) is treated with PyBOP (196 mg, 0.376 mmol) for 30 minutes.
- a THF solution (6 mL) of compound clvii ( ⁇ 0.47 mmol) and DIPEA (0.327 mL, 1.88 mmol) is then added to the above solution.
- the reaction mixture is stirred at room temperature overnight and quenched with water (30 minutes).
- the reaction mixture is extracted with EtOAc (50 mL).
- the organic phase is washed with NaHCO 3 and brine.
- the combined aqueous layers are back extracted with EtOAc (50 mL).
- the combined organic phases are dried and concentrated in vacuo .
- the resultant residue is purified by silica gel chromatography (80-100 EtOAc/hexanes) to yield compound clxi (104 mg, 48%).
- compound clxxvii [(S)-(-)-2-oxo 1,5 imidazoline dicarboxylic acid 1-benzyl ester] (290 mg, 1.1 mmol) is dissolved in anhydrous DMF (6 mL). HOAt (151 mg, 1.2 mmol) is added and the reaction is stirred at room temperature for 25 minutes. The reaction is then cooled down in an ice bath. DIC (0.2 mL, 0.16 g, 1.2 mmol) is then added followed by the addition of compound clxxviii (1 mmol, 435 mg.) in anhydrous DMF (4 mL). The reaction is allowed to rise slowly to room temperature and stirred for 2 days.
- the starting material clxxix (434 mg, 0.64 mmol) is dissolved in Dioxane (6 mL) and 0.5 M aqueous NaOH solution (4 mL, 3 eq.). The reaction is run overnight. TLC in 100% EtOAc (using PMA stain) shows in addition to the expected acid product at the origin, a faster running product.
- the reaction mixture is acidified to pH 2 with 1 N HCl, and then extracted 2X with EtOAc. Solid NaCl is added to the aqueous solution to facilitate the extraction.
- the organic extracts are then combined, dried over MgSO 4 and evaporated under reduced pressure. MS indicates that the CBZ group is removed by the hydrolysis.
- the resulting compound clxxx (quantitative yield) is used as is in the next step.
- 6-hydroxy picolinic (153mg, 1.1 mmol) is dissolved in anhydrous DMF (6 mL).
- HOAt 151 mg, 1.2 mmol
- DIC 0.2 mL. 0.16 g, 1.2 mmol
- clxxxii 1.0 mmol, 435 mg.
- reaction is allowed to rise slowly to room temperature and stirred for 2 days.
- the reaction is then dumped in a separatory funnel containing 120 mL of EtOAc and washed 2X with 1 N. HCl (50 mL) and 1X with brine.
- the organic layer is separated, dried over MgSO 4 .
- the solvent is evaporated by reduced pressure and the product purified by chromatography on silica gel (load in DCM, elute with 30%, then 50% EtOAc/DCM, and then 2% MeOH/EtOAc) to yield compound clxxxiii collected (314 mg, 56%).
- the starting material clxxxiii (314 mg, 0.56 mmol) is dissolved in dioxane (5 mL) and 0.5 M NaOH (3.4 mL, 3 eq). The reaction is run overnight. TLC in 100% EtOAc (using UV) shows complete conversion to the slow running acid product at the origin. The reaction is acidified to pH 2 with 1 N HCl and then extracted 2X with EtOAc. Solid NaCl is added to the aqueous to facilitate the extraction. The organic extracts are then combined, dried over MgSO 4 and then evaporated under reduced pressure to yield compound clxxxiv (0.5 mmol, 89%) that is used as is in the next step.
- Diaminopropionic acid (3 g, 28.7 mmol) is taken up in 1 M NaOH (86.2 mL, 86.2 mmol) and cooled to 0°C, and then MeOC(O)Cl (5.54 mL, 71.75 mmol) is added in Et 2 O(25 mL). The resulting mixture stirred overnight warming to room temperature. The reaction mixture pH is lowered to 2 and aqueous layer is extracted 3x with EtOAc. Extracts are combined and dried over Na 2 SO 4 filtered and concentrated to yield compound clxxxix (3.09 g, 48.9%).
- 2-Pyrazinecarboxylic acid (1 g, 8 mmol, 1 eq) is dissolved in DCM (15 mL) with addition of HOAt (1.1 g, 8 mmol) and DCC (8 mL, 1 M) in DCM. After stirring at room temperature for 20 minutes, compound clxxxxv (1.3 g, 8 mmol) is added to the activated mixture. DIPEA (2 mL, 12 mmol) is added subsequently, followed by DMAP (1.5 g, 12 mmol). After stirring over 3 days at room temperature, the reaction mixture is filtered through celite, concentrated and the desired product clxxxxvi is purified by column chromatography (50% EtOAc/hexane) as yellow oil (2.1 g, 100%).
- the (-)-alpha-(4-pyridyl)ethyl amine is obtained from the tartrate salt of (-)-alpha-(4-pyridyl)ethyl amine (Aldrich) by stirring with 1 N NaOH (2 eq) for 1 hour followed by extraction with EtOAc (3x) 70% recovery]. The reaction is stirred overnight at room temperature. The reaction mixture is washed with saturated NaHCO 3 and brine. The product is purified in 5% EtOH/EtOAc to yield 2 g (99%) of intermediate compound cdx.
- an invention herein is directed to the use of the compounds according to the invention in the manufacture of a medicament for inhibiting HCV protease comprising contacting an anti-HCV protease inhibitory amount of a compound BW or CU with a composition comprising HCV protease.
- Yet another invention herein is directed to the use of the compounds according to the invention in the manufacture of a medicament for inhibiting replication of HCV comprising contacting HCV with an effective amount of a compound BW or CU.
- another invention herein is directed to the use of the compounds according to the invention in the manufacture of a medicament for treating a patient suffering from or subject to an HCV infection comprising administering to the patient a pharmaceutically effective amount of compound BW or CU.
- References herein to treating an HCV infection should be understood to include prophylactic therapy to prevent or inhibit the infection as well as the treatment of an established acute or chronic HCV infection or physiological conditions associated with HCV infection to essentially cure the patient of the infection, inhibit the degree (amount) of infection or ameliorate the physiological conditions associated therewith.
- Effective amount is meant to describe an amount of the compound of the present invention effective within the scope of reasonable biological judgement, suitable for use in contact with the cells of humans and other mammals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio in treating an HCV infection and thus producing the desired therapeutic effect.
- Physiological conditions discussed herein include some, but not all, of the possible clinical situations where an anti-HCV treatment is warranted. Those experienced in this field are well aware of the circumstances requiring either an anti-HCV treatment.
- a particular aspect of the invention provides for a compound according to the invention to be administered in the form of a pharmaceutical composition, though the compound may be administered alone.
- “Pharmaceutical composition” means a composition comprising a compound BW or CU and at least one component selected from the group comprising pharmaceutically acceptable carriers, diluents, coatings, adjuvants, excipients, or vehicles, such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, emulsion stabilizing agents, suspending agents, isotonic agents, sweetening agents, flavoring agents, perfuming agents, coloring agents, antibacterial agents, antifungal agents, other therapeutic agents, lubricating agents, adsorption delaying or promoting agents, and dispensing agents, depending on the nature of the mode of administration and dosage forms.
- compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups.
- suspending agents include ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances.
- Exemplary antibacterial and antifungal agents for the prevention of the action of microorganisms include parabens, chlorobutanol, phenol, sorbic acid, and the like.
- Exemplary isotonic agents include sugars, sodium chloride and the like.
- Exemplary adsorption delaying agents to prolong absorption include aluminum monosterate and gelatin.
- Exemplary adsorption promoting agents to enhance absorption include dimethyl sulphoxide and related analogs.
- Exemplary carriers, diluents, solvents, vehicles, solubilizing agents, emulsifiers and emulsion stabilizers include water, chloroform, sucrose, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, tetrahydrofurfuryl alcohol, benzyl benzoate polyols, propylene glycol, 1,3-butylene glycol, glycerol, polyethylene glycols, dimethylformamide, Tween ® 60, Span ® 80, cetostearyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate, fatty acid esters of sorbitan, vegetable oils (such as cottonseed
- Exemplary excipients include lactose, milk sugar, sodium citrate, calcium carbonate, dicalcium phosphate phosphate.
- Exemplary disintegrating agents include starch, alginic acids and certain complex silicates.
- Exemplary lubricants include magnesium stearate, sodium lauryl sulphate, talc, as well as high molecular weight polyethylene glycols.
- anti-HCV agents include immunomodulatory agents, such as ⁇ - ⁇ - or ⁇ -interferons; pegylated derivatized interferon- ⁇ compounds, other antiviral agents such as ribavirin and amantadine; other inhibitors of hepatitis C protease; inhibitors of other targets in the HCV life cycle including the helicase, polymerase, metalloprotease, internal ribosome entry, or broad-spectrum antiviral compounds such as VX 497, an inhibitor of cellular inosine monophosphate dehydrogenase, IMPDH, covered by United States Patent No. 5,807,876 ; or combinations thereof.
- Therapeutic agents used in combination with a compound of the present invention may be administered separately, simultaneously or sequentially.
- the choice of material in the pharmaceutical composition other than the compound BW or CU is generally determined in accordance with the chemical properties of the active compound such as solubility, the particular mode of administration and the provisions to be observed in pharmaceutical practice.
- excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used for preparing tablets.
- compositions may be presented in assorted forms such as tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups.
- Liquid dosage form means the dose of the active compound to be administered to the patient is in liquid form, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such solvents, solubilizing agents and emulsifiers.
- Solid compositions may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like.
- aqueous suspensions When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension.
- the oily phase of the emulsion pharmaceutical composition may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier that acts as a stabilizer. It is also preferred to include both an oil and a fat.
- the emulsifier(s) with or without stabilizer(s) make up the emulsifying wax, and the way together with the oil and fat make up the emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
- the aqueous phase of the cream base may include, for example, a least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
- a polyhydric alcohol i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
- the topical formulations may desirably include a compound that enhances absorption or penetration of the active ingredient through the skin or other affected areas.
- the choice of suitable oils or fats for a formulation is based on achieving the desired cosmetic properties.
- the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
- Straight or branched chain, mono- or dibasic alkyl esters such as diisopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
- a compound/pharmaceutical compositions of the present invention may be administered in a suitable formulation to humans and animals by topical or systemic administration, including oral, inhalational, rectal, nasal, buccal, sublingual, vaginal, colonic, parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), intracisternal and intraperitoneal. It will be appreciated that the preferred route may vary with for example the condition of the recipient.
- “Pharmaceutically acceptable dosage forms” refers to dosage forms of the compound of the invention, and includes, for example, tablets, dragees, powders, elixirs, syrups, liquid preparations, including suspensions, sprays, inhalants tablets, lozenges, emulsions, solutions, granules, capsules and suppositories, as well as liquid preparations for injections, including liposome preparations. Techniques and formulations generally may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, latest editi on.
- Forms suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
- Compressed tables may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
- Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compounds moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
- Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.
- the compounds can be microencapsulated in, or attached to, a slow release or targeted delivery systems such as a biocompatible, biodegradable polymer matrices (e.g., poly(d,l-lactide co-glycolide)), liposomes, and microspheres and subcutaneously or intramuscularly injected by a technique called subcutaneous or intramuscular depot to provide continuous slow release of the compound(s) for a period of 2 weeks or longer.
- a biocompatible, biodegradable polymer matrices e.g., poly(d,l-lactide co-glycolide)
- liposomes e.g., liposomes
- microspheres e.g., liposomes, and microspheres and subcutaneously or intramuscularly injected by a technique called subcutaneous or intramuscular depot to provide continuous slow release of the compound(s) for a period of 2 weeks or longer.
- the compounds may be sterilized, for example, by filtration through a bacteria
- Forms suitable for nasal or inhalational administration means formulations which are in a form suitable to be administered nasally or by inhalation to a patient.
- the formulation may contain a carrier, in a powder form, having a particle size for example in the range 1 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc.)
- Suitable formulations wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops include aqueous or oily solutions of the active ingredient.
- Formulations suitable for aerosol administration may he prepared according to conventional methods and may be delivered with other therapeutic agents. Inhalational therapy is readily administered by metered dose inhalers.
- Forms suitable for oral administration means formulations which are in a form suitable to be administered orally to a patient.
- the formulations may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- Forms suitable for parenteral administration means formulations that are in a form suitable to be administered parenterally to a patient.
- the formulations are sterile and include emulsions, suspensions, aqueous and non-aqueous injection solutions, which may contain suspending agents and thickening agents and anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic, and have a suitably adjusted pH, with the blood of the intended recipient.
- Forms suitable for rectal or vaginal administrations means formulations that are in a form suitable to be administered rectally or vaginally to a patient.
- the formulation is preferably in the form of suppositories that can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
- Forms suitable for systemic administration means formulations that are in a form suitable to be administered systemically to a patient.
- the formulation is preferably administered by injection, including transmuscular, intravenous, intraperitoneal, and subcutaneous.
- the compounds of the invention are formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution.
- the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included.
- Systematic administration also can be by transmucosal or transdermal means, or the compounds can be administered orally.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, bile salts and fusidic acid derivatives for transmucosal administration.
- detergents may be used to facilitate permeation.
- Transmucosal administration may be through use of nasal sprays, for example, or suppositories.
- the compounds are formulated into conventional oral administration forms such as capsules, tablets, and tonics.
- Forms suitable for topical administration means formulations that are in a form suitable to be administered topically to a patient.
- the formulation may be presented as a topical ointment, salves, powders, sprays and inhalants, gels (water or alcohol based), creams, as is generally known in the art, or incorporated into a matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier.
- the active ingredients may be employed with either a paraffinic or a water-miscible ointment base.
- the active ingredients may be formulated in a cream with an oil-in-water cream base.
- Fomulations suitable for topical administration in the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
- Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- Solid dosage form means the dosage form of the compound of the invention is solid form, for example capsules, tablets, pills, powders, dragees or granules.
- the compound of the invention is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as
- Actual dosage levels of active ingredient(s) in the compositions of the invention may be varied so as to obtain an amount of active ingredient(s) that is (are) effective to obtain a desired therapeutic response for a particular composition and method of administration for a patient.
- a selected dosage level for any particular patient therefore depends upon a variety of factors including the desired therapeutic effect, on the route of administration, on the desired duration of treatment, the etiology and severity of the disease, the patient's condition, weight, sex, diet and age, the type and potency of each active ingredient, rates of absorption, metabolism and/or excretion and other factors.
- Total daily dose of the compounds of this invention administered to a patient in single or divided doses may be in amounts, for example, of from about 0.001 to about 100 mg/kg body weight daily and preferably 0.01 to 10 mg/kg/day.
- the doses are generally from about 0.01 to about 100, preferably about 0.01 to about 10, mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.01 to about 50, preferably 0.01 to 10, mg/kg body weight per day by intravenous administration.
- the percentage of active ingredient in a composition may be varied, though it should constitute a proportion such that a suitable dosage shall be obtained.
- Dosage unit compositions may contain such amounts of such - submultiples thereof as may be used to make up the daily dose.
- several unit dosage forms may be administered at about the same time.
- a dosage may be administered as frequently as necessary in order to obtain the desired therapeutic effect.
- Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate.
- it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. It goes without saying that, for other patients, it will be necessary to prescribe not more than one or two doses per day.
- the formulations can be prepared in unit dosage form by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier that constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
- the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials with elastomeric stoppers, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- sterile liquid carrier for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- HCV NS3 protease domain was expressed and purified as described previously (Vertex, PCT publication W098/17679 ; which is incorporated herein by reference).
- the chromogenic peptide substrate, EDVVAbuC-p-nitroanilide, and the NS4A cofactor fragment (-KKGSVVIVGRIVLSGK-) for NS3 protease was custom synthesized by American Peptide Corn (Ca).
- the compounds of this invention were tested for their ability to inhibit HCV NS3 protease activity using a spectrophotometric assay with EDVVAbuC-p-nitroanilide as substrate.
- the assay was run in a 96-well microtiter plate using a SpectraMax 250 reader (Molecular Devices, Sunnyvale, CA) with kinetic capability.
- Cleavage of EDVVAbuC-p-nitroanilide (500 ⁇ M) substrate by purified HCV NS3 protease (0.5 ⁇ M) was performed at 30°C in the buffer containing 30 ⁇ M NS4A fragment, 46mM Hepes, pH 8.0, 92 mM NaCl, 18% glycerol, 5 mM DTT, and 7.5% DMSO in the absence or presence of the testing compound.
- the reaction was monitored for pNA (p-nitroaniline) release at 405 nm.
- Ki values are calculated from rate vs . [inhibitor] plots, at fixed concentrations of enzyme and substrate, by a nonlinear least squares fit of the data to the equation of Morrison for tight binding competitive inhibition [ J. F. Morrison, Biochem. Biophys. Acta. 185 269-286 (1969) ].
- the Prism program (GraphPad Software, Inc.) is used for this procedure.
- anti-HCV activity refers to the capacity of a molecule, when present, to completely inhibit or reduce accumulation of HCV virions compared to HCV virion accumulation in the absence of such molecule, and/or the capacity of a molecule to reduce or ameliorate conditions or symptoms associated with HCV infection or pathogenesis in patients.
- Molecules having anti-HCV activity include those that disrupt one or more steps in HCV infection or replication, as well as those that evoke immunomodulating and antiproliferative actions in host cells.
- Molecules having anti-HCV activity can inhibit HCV-specific replicative events such as, but not limited to, HCV-directed nucleic acid or protein synthesis.
- Stages of HCV replication at which molecules having anti-HCV activity can act include-cell entry (e.g., attachment; penetration); uncoating and release of the HCV genome; replication of the HCV genome (e.g., replication of either strand of the viral RNA genome; transcription of viral messenger RNA); translation of HCV proteins; posttranslational modification of HCV proteins (e.g., proteolytic cleavage; glycosylation); intracellular transport of viral proteins; assembly of virion components; and release of viral particles (e.g., budding).
- Classes of molecules having anti-viral activity include, but are not limited to soluble receptor decoys and antireceptor antibodies; ion channel blockers, capsid stabilizers, and fusion protein inhibitors; inhibitors of viral polymerases, reverse transcriptase, helicase, primase, or integrase; antisense oligonucleotides and ribozymes; immunomodulating and immunostimulating agents, including cytokines such as interferons, as well as peptide agonists, steroids, and classic drugs such as levamisole; inhibitors of regulatory proteins; protease inhibitors; assembly protein inhibitors; and antiviral antibodies and cytotoxic lymphocytes.
- anti-HCV effective amount or “pharmaceutically effective amount” refers to an amount of a compound, or combination of compounds as disclosed herein, effective in reducing or ameliorating conditions or symptoms associated with HCV infection or associated pathogenesis in patients, or in reducing viral levels in vitro or in vivo .
- In vitro applications include the Replicon Assay system, described below, where such amounts are effective in reducing HCV replicon RNA accumulation and/or the accumulation of proteins encoded by genes contained therein.
- Compounds having anti-HCV activity contemplated for use in the compositions and methods of combination therapy disclosed herein include, but are not limited to, immunomodulatory molecules, including immunostimulatory cytokines, and other compounds known to have HCV antiviral activity, such as various antiviral nucleosides and nucleotides.
- Immunomodulatory molecules contemplated for use in combination with the HCV serine protease inhibitors disclosed herein include, but are not limited to, interferon-alpha 2B (Intron A, Schering Plough); Rebatron (Schering Plough, Interferon-alpha 2B + Ribavirin); pegylated interferon alpha ( Reddy, K.R. et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
- interferon-alpha 2B Intron A, Schering Plough
- Rebatron Desatron (Schering Plough, Interferon-alpha 2B + Ribavirin
- pegylated interferon alpha Reddy, K.R. et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon
- Interferons may ameliorate viral infections by exerting direct antiviral effects and/or by modifying the immune response to infection.
- the antiviral effects of interferons are often mediated through inhibition of viral penetration or uncoating, synthesis of viral RNA, translation of viral proteins, and/or viral assembly and release.
- Patent 4,835,168 Colacino, J.M. et al. Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt. Antimicrobial Agents & Chemotherapy 34, 2156-2163 (1990) ); and 9-Hydroxyimino-6-methoxy-1,4a-dimethyl-1,2,3,4,4a,9, 10, 10a-octahydro-phenanthrene-1-carboxylic acid methyl ester; 6-Methoxy-1 ,4a- dimethyl-9-(4-methyl-piperazin-1-ylimino)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid methyl ester-hydrochloride: 1-(2-Chloro-phenyl)-3-(2,2-diphenyl-ethyl)-urea ( U.S. Patent 6.127.422 ).
- Formulations, doses, and routes of administration for the foregoing molecules are either taught in the references cited below, or are well-known in the art as disclosed, for example, in F.G. Hayden, in Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, Hardman et al., Eds., McGraw-Hill, New York (1996), Chapter 50, pp. 1191-1223 , and the references cited therein.
- a pharmaceutically effective amount of that compound can be determined using techniques that are well-known to the skilled artisan. Note, for example, Benet et al, in Goodman & Gilman's The Pharmacological Basis of Therapeutics.
- the drug combinations of the present invention can be provided to a cell or cells, or to a human patient, either in separate pharmaceutically acceptable formulations administered simultaneously or sequentially, formulations containing more than one therapeutic agent, or by an assortment of single agent and multiple agent formulations. However administered, these drug combinations form an anti-HCV effective amount of components.
- immunomodulators and immunostimulants that can be used in the methods of the present invention are currently available and include: AA-2G; adamantylamide dipeptide; adenosine deaminase; Enzon; adjuvant, Alliance; adjuvants, Ribi; adjuvants, Vaxcel; Adjuvax; agelasphin-11; AIDS therapy, Chiron; algal glucan, SRI; algammulin, Anutech; Anginlyc; anticellular factors, Yeda; Anticort; antigastrin-17 immunogen, Ap; antigen delivery system, Vac; antigen formulation, IDBC; antiGnRH immunogen, Aphton; Antiherpin; Arbidol; azarole; Bay-q-8939; Bay-r-1005; BCH-1393; Betafectin; Biostim; BL-001; BL-009; Broncostat; Cantastim; CDR1-84-246; cefodizime;
- ICOS CMV peptides, City of Hope; CN-5888; cytokine-releasing agent, St; DHEAS, Paradigm; DISC TA-HSV; JO7B; IOIA; IOIZ; ditiocarb sodium, ECA-10-142; ELS-1; endotoxin, Novartis; FCE-20696; FCE-24089; FCE-24578; FLT-3 ligand, Immunex; FR-900483; FR-900494; FR-901235; FTS-Zn G-proteins, Cadus; gludapcin; glutaurine; glycophosphopeptical; GM-2; GM-53; GMDP; growth factor vaccine, EntreM; H-BIG, NABI; H-CIG, NABI; HAB-439; Helicobacter pylori vaccine; herpes-specific immune factor; HIV therapy, United Biomed; HyperGAM+CF; ImmuMax; Immun BCG; immune therapy, Connective;
- nucleoside and nucleotide compounds useful in the present invention include, but are not limited to: (+) -cis-5-fluoro-1- [2-(hydroxy-methyl) - 1,3-oxathiolan -5-yl]cytosine; (-) -2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC); (-) -cis-5-fluoro-1-[2-(hydroxy-methyl) - [1,3-oxathiolan-5-yl]cytosine (FTC); (-) 2', 3', dideoxy-3'-thiacytidine [(-)-SddC]; 1- (2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) -5-iodocytosine (FIAC); 1- (2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) -5-iodocytosine triphosphate (FIACTP); 1-
- nucleoside analogs are generally employed as antiviral agents as is, nucleotides (nucleoside phosphates) must sometimes have to be converted to nucleosides in order to facilitate their transport across cell membranes.
- An example of a chemically modified nucleotide capable of entering cells is S-1-3-hydroxy-2-phosphonylmethoxypropyl cytosine HPMPC, Gilead Sciences).
- Nucleoside and nucleotide compounds of this invention that are acids can form salts. Examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium, or magnesium, or with organic bases or basic quaternary ammonium salts.
- Immunomodulators and immunostimulants useful in the combination therapy methods of the present invention can be administered in amounts lower than those conventional in the art.
- interferon alpha is typically administered to humans for the treatment of HCV infections in an amount of from about 1 x 10 6 units/person three times per week to about 10 x 10 6 units/person three times per week ( Simon et al., Hepatology 25:445-448 (1997) ).
- this dose can be in the range of from about 0.1 x 10 6 units/person three times per week to about 7.5 x 10 6 units/person three times per week; more preferably from about 0.5 x 10 6 units/person three times per week to about 5 x 10 6 units/person three times per week; most preferably from about 1 x 10 6 units/person three times per week to about 3 x 10 6 units/person three times per week. Due to the enhanced hepatitis C virus antiviral effectiveness of immunomodulators and immunostimulants in the presence of the HCV serine protease inhibitors of the present invention, reduced amounts of these immunomodulators/immunostimulants can be employed in the methods and compositions disclosed herein.
- HCV serine protease inhibitors due to the enhanced hepatitis C virus antiviral effectiveness of the present HCV serine protease inhibitors in the presence of immunomodulators and immunostimulants, reduced amounts of these HCV serine protease inhibitors can be employed in the methods and compositions disclosed herein. Such reduced amounts can be determined by routine monitoring of hepatitis C virus titers in infected patients undergoing therapy. This can be carried out by, for example, monitoring HCV RNA in patients' serum by slot-blot, dot-blot, or RT-PCR techniques, or by measurement of HCV surface or other antigens.
- Patients can be similarly monitored during combination therapy employing the HCV serine protease inhibitors disclosed herein and other compounds having anti-HCV activity, for example nucleoside and/or nucleotide antiviral agents, to determine the lowest effective doses of each when used in combination.
- HCV serine protease inhibitors disclosed herein and other compounds having anti-HCV activity for example nucleoside and/or nucleotide antiviral agents, to determine the lowest effective doses of each when used in combination.
- nucleoside or nucleotide antiviral compounds can be administered to humans in an amount in the range of from about 0.1 mg/person/day to about 500 mg/person/day; preferably from about 10 mg/person/day to about 300 mg/person/day; more preferably from about 25 mg/person/day to about 200 mg/person/day; even more preferably from about 50 mg/person/day to about 150 mg/person/day; and most preferably in the range of from about 1 mg/person/day to about 50 mg/person/day.
- Doses of compounds can be administered to a patient in a single dose or in proportionate multiple subdoses.
- dosage unit compositions can contain such amounts of submultiples thereof to make up the daily dose. Multiple doses per day can also increase the total daily dose should this be desired by the person prescribing the drug.
- the regimen for treating a patient suffering from a HCV infection with the compounds and/or compositions of the present invention is selected in accordance with a variety of factors, including the age, weight, sex, diet, and medical condition of the patient, the severity of the infection, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the particular compounds employed, and whether a drug delivery system is utilized.
- Administration of the drug combinations disclosed herein should generally be continued over a period of several weeks to several months or years until virus titers reach acceptable levels, indicating that infection has been controlled or eradicated.
- Patients undergoing treatment with the drug combinations disclosed herein can be routinely monitored by measuring hepatitis viral RNA in patients serum by slot-blot, dot-blot, or RT-PCR techniques, or by measurement of hepatitis C viral antigens, such as surface antigens, in serum to determine the effectiveness of therapy. Continuous analysis of the data obtained by these methods permits modification of the treatment regimen during therapy so that optimal amounts of each component in the combination are administered, and so that the duration of treatment can be determined as well.
- the treatment regimen/dosing schedule can be rationally modified over the course of therapy so that the lowest amounts of each of the antiviral compounds used in combination which together exhibit satisfactory anti-hepatitis C virus effectiveness are administered, and so that administration of such antiviral compounds in combination is continued only so long as is necessary to successfully treat the infection.
- the present invention encompasses the use of the HCV serine protease inhibitors disclosed herein in various combinations with the foregoing and similar types of compounds having anti-HCV activity to treat or prevent HCV infections in patients.
- one or more HCV serine protease inhibitors can be used in combination with: one or more interferons or interferon derivatives having anti-HCV activity; one or more non-interferon compounds having anti-HCV activity; or one or more interferons or interferon derivatives having anti-HCV activity and one or more non-interferon compounds having anti-HCV activity.
- any of the presently disclosed HCV serine protease inhibitors and foregoing compounds having anti-HCV activity can be present in a pharmaceutically or anti-HCV effective amount.
- each can also be present in a subclinical pharmaceutically effective or anti-HCV effective amount, i.e. an amount that, if used alone, provides reduced pharmaceutical effectiveness in completely inhibiting or reducing the accumulation of HCV virions and/or reducing or ameliorating conditions or symptoms associated with HCV infection or pathogenesis in patients compared to such HCV serine protease inhibitors and compounds having anti-HCV activity when used in pharmaceutically effective amounts.
- the present invention encompasses the use of combinations of HCV serine protease inhibitors and compounds having anti-HCV activity as described above to treat or prevent HCV infections, where one or more of these inhibitors or compounds is present in a pharmaceutically effective amount, and the other(s) is(are) present in a subclinical pharmaceutically effective or anti-HCV effective amount(s) owing to their additive or synergistic effects.
- additive effect describes the combined effect of two (or more) pharmaceutically active agents that is equal to the sum of the effect of each agent given alone.
- a synergistic effect is one in which the combined effect of two (or more) pharmaceutically active agents is greater than the sum of the effect of each agent given alone.
- HCV hepatitis C virus
- HCV serine protease inhibitors i.e. Compound CU, Comparison Compound EP, and Comparison Compound EC
- interferon alpha-2B Schering Plough
- interferon alpha-2A PBL Biomedical Laboratories, New Brunswick, NJ
- interferon beta Research Diagnostics Inc, Flanders, NJ
- ovine-interferon tau Research Diagnostics Inc, Flanders, NJ
- the Replicon Assay measures the amount of HCV subgenomic RNA (replicon R remaining in replicon cells ( Lohmann et al. Science 285: 110-113 (1999) ) after two days of drug treatment relative to the amount of replicon RNA in untreated cells.
- the potency of compounds as HCV antiviral drugs is directly proportional to the level of inhibition of replicon RNA accumulation.
- the two drugs are tested in combinations in the in vitro Replicon Assay system to determine whether, when used together, they exhibit additive or synergistic anti-HCV activity.
- the Replicon Assay is employed as a surrogate model for in vitro HCV infection to evaluate the combined effects of the immunomodulator, for example interferon-alpha 2B ((Intron A); Schering Plough), and the HCV serine protease inhibitor, for example Compound CU.
- the results demonstrate that there is a clear synergistic anti-HCV effect of these two types of drugs as measured using formal mathematical determinations of synergy to analyze their capacity to reduce HCV RNA levels in the Replicon Assay.
- the Replicon Assay employing a cell line containing the self-replicating HCV subgenomic RNA (replicon) is described in Lohmann et al. Science 285:110-113 (1999) .
- Genbank accession number for the sequence of the replicon used in the experiments described herein is listed in this reference as AJ242654.
- This paper discloses methods for in vitro transcription of RNA from the replicon cDNA, transfection of the replicon RNA into Huh7 cells by electroporation, and selection of cells containing the replicon RNA using the antibiotic G418, Huh7 cells are a hepatoma cell line obtained from Dr. William Mason at Fox Chase Cancer Research Center (Philadelphia).
- Replicon Assay is performed as described in detail below. Briefly, Replicon cells are placed in 96 well trays at a density of 10,000 cells per well and incubated 37°C. The cells are incubated in DMEM (Dulbecco's Minimal Essential Media) supplemented with 10% fetal bovine serum, glutamine, nonessential amino acids, and the antibiotic G418 (0.25 mg/ml). After overnight incubation, the medium is replaced with DMEM containing 2% fetal bovine serum and various concentrations of the serine protease inhibitor, such as Compound CU, and/or an interferon such as interferon-alpha 2B (Intron A, Schering Plough). Each compound is tested at six to eight different concentrations.
- DMEM Disbecco's Minimal Essential Media
- concentrations of the compounds that will result in almost complete inhibition of replicon RNA accumulation after two days of treatment are selected. From these starting concentrations, serial dilutions are made so that the concentration ranges tested in the Replicon Assay include concentrations at which the compounds are highly effective, as well as concentrations at which there is no significant effect.
- concentration ranges tested in the Replicon Assay include concentrations at which the compounds are highly effective, as well as concentrations at which there is no significant effect.
- Each HCV serine protease inhibitor concentration is tested without any added interferon, as well as with the addition of six to eight different interferon doses. Similarly, interferon is tested without any added HCV serine protease inhibitor.
- RNA is extracted from the cells using the RNeasy-96 kit manufactured by Qiagen Inc. (Valencia, CA). This RNA is then analyzed by quantitative RT-PCR, or TaqMan ® (Applied Biosystems, Foster City CA).
- the TaqMan ® RT-PCR target is the neomycin resistance gene in the replicon RNA.
- the plates are configured so that there are 5 replicates of each drug treatment sample, and 16 replicates of the untreated samples. This permits greater statistical confidence in the quantitative RT-PCR data.
- the IC 50 has a percent coefficient of variation (%CV or 100% x standard deviation in the IC 50 /mean IC 50 ) of about 20%.
- the IC 50 is the value used to rank individual compounds tested in this assay based on their potency as HCV antiviral agents. Simple IC 50 determinations are inadequate to assess the utility of compounds used in combination.
- the most effective analysis of the array of data generated using all the combinations of different interferons and serine protease inhibitors requires evaluation of the percent inhibitions as shown in Table 7 using mathematical methods described below that are designed to determine if combination treatments are agonistic, additive, or synergistic.
- the Replicon Assay is used to measure the capacity of potential HCV antiviral compounds to inhibit the accumulation of a HCV subgenomic RNA replicon molecule in a Huh7 cell line ( Lohmann et al. Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line. Science 285, 110-113 (1999) ).
- This assay comprises three operational components : (1) Replicon cell maintenance, assay plate set up, and compound application; (2) Extraction of total cellular RNA from replicon cells; and (3) Real time RT-PCR (TaqMan ® ) to measure the mount of replicon RNA in each sample.
- the Replicon Assay requires at least 4 days to perform; however, the process can be interrupted and samples frozen between steps. Each assay component is described below.
- Replicon cell maintenance, assay plate setup, and compound application 1.1 Replicon cell line maintenance
- the cell line used in the Replicon Assay is produced as described in Lohmann et al. (Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line. Science 285, 110-113 (1999) ). After 150 cm 2 cell culture flasks (Costar) containing Replicon cells are incubated at 37°C and 5% CO 2 and become confluent, the cells are diluted 1:10, v/v, into fresh 150 cm 2 cell culture flasks.
- the medium is DMEM containing 10% fetal bovine serum (FBS). IX non-essential amino acids (NEAA), 1X Glutamine (Glu), and 0.25 mg/ml G418. Three serial passages are performed, each time allowing the cells to become confluent, followed by dilution of the cells into fresh 150 cm 2 cell culture flasks. These cells, referred to as "original cells,” are then aliquoted and stored for future use in the Replicon Assay. TaqMan ® -based analysis is performed to determine the number of HCV replicon genomes per cell, which reveals the presence of ⁇ 150 copies of the replicon per cell. This is based on the ratio of copies of replicon RNA to two times the copies of the human apo B gene (number of haploid genomes).
- HCV serine protease inhibitor (HSPI) and an interferon in combination can be assessed in the Replicon Assay by generating a dose response curve for the HSPI in the presence of various levels of interferon, or by determining a dose response curve for an interferon in the presence of various levels of HSPI.
- the goal is to assess whether there is more or less inhibition of viral RNA accumulation than would be expected if the two drugs produce additive effects on the RNA. More specifically, the additivity definition of Lowe ((1928) Die Quantitation Vand der Pharmakologie Ergebn. Physiol., 27, 47-187 ) is used. This is defined as follows. Let D E,INF be the concentration of interferon that results in effect E, and let D E,HSPI be the concentration of protease inhibitor that results in effect E.
- the degree of synergy or antagonism is expressed in terms of iso-effect curves or Isobols.
- the combination (D1, D2) is a point on a graph where the axes are the concentrations of interferon and HSPI ( Fig. 2 ). All such combinations that produce an effect level E form the E effect Isobol. It is necessarily the case that (D E,INF ,0) and (0, D E,HSPI ) are points on the Isobol.
- the Isobols are straight lines connecting points (D E,INF ,0) and (0, D E,HSPI ) when the additivity relationship (1) is satisfied.
- Concave-up Isobols indicate synergy, and concave-down Isobols indicate antagonism.
- Concave-up Isobols indicate synergy, and concave-down Isobols indicate antagonism.
- the equation defines a response surface that can be fit to the percent control values at all treatment combinations. Contour plots from this fitted response surface are the Isobols.
- the response surface model assumes a sigmoidal dose response for each compound defined by (2).
- E E max 1 + Drug IC ⁇ 50 m + B
- the parameter a measures the amount of interaction.
- this equation can be solved to give the effect that results from any treatment combination [INF] and [HSPI]. Therefore, this equation defines a response surface.
- the parameters can be chosen using nonlinear weighted least squares regression.
- the parameter ⁇ can be related to a synergy measure S ( Hewlett, P. S.
- HCV serine protease inhibitor Compound CU is tested over a concentration range from 3 ⁇ M to 0.0123 ⁇ M. i.e., a 224-fold range.
- the interferon-alpha 2B concentrations vary from 30 units per sample to 0.0096 units per sample, i.e., a 3125-fold range.
- Compound CU when used as a single drug treatment, Compound CU exhibits an IC 50 of 0.48 ⁇ M, and the interferon IC 50 is 2.19 U.
- addition of interferon-alpha 2B results in an increase in the inhibition of replicon RNA accumulation in a dose-dependent manner.
- treatment of cells with 0.333 ⁇ M Compound CU results in 28% inhibition of replicon RNA accumulation.
- Treatment of cells with a combination of 0.333 ⁇ M Compound CU, which is 71% of the IC 50 dose (0.469 ⁇ M) and 0.24 U of interferon-alpha 2B, which is 11% of the interferon-alpha 2B IC 50 (2.05 ⁇ M) results in a 49% inhibition of replicon RNA accumulation.
- 71 % of one IC 50 dose in combination with 11% of the other results in 49% inhibition of replicon RNA accumulation.
- Table 8 summarizes further results obtained in the Replicon Assay after treatment of replicon cells for 48 hours with various HCV serine protease inhibitors of the present invention and several different interferons, individually or in combination.
- the standard deviation of values measured for inhibition of HCV replicon RNA in the Replicon Assay is ⁇ 20%.
- Compounds are tested over a broad concentration range and at lower compound concentrations that cause no significant inhibition of HCV replicon RNA concentration. Because of the ⁇ 20% standard deviation of the assay, some data points will generate negative numbers. Negative inhibition numbers indicate in a particular experiment there is on average more HCV replicon RNA molecules in the compound treated samples than in the mock treated samples.
- IFN alpha-2B (units) 30.00 6.00 1.20 0.24 0.048 0.0096 0.000 0.000 89% 73% 38% 16% 8% 12% 0% Compound 0.012 92% 78% 44% 20% 19% 19% 6% CU 0.037 92% 78% 25% 21% 2% 7% 8% 0.111 93% 79% 46% 29% 12% 15% 11% ( ⁇ M) 0.333 94% 87% 66% 49% 33% 27% 28% 1.000 99% 98% 96% 95% 92% 93% 88% 3.000 99% 99% 99% 99% 98% 98% 98% EXPERIMENT 2 IFN alpha-2A (units) 30 6 1.2 0.24 0.048 0.0096 0 n 66% 61% 27%
- Another measure for evaluating the synergistic nature of anti-HCV drug treatment using the present HCV serine protease inhibitors and interferons is to use the same methods described above to evaluate the current standard combination therapy for HCV, i.e., interferon alpha-2B in combination with Ribavirin in the Replicon Assay.
- the last line of Table 9 shows that the ⁇ parameter for a mixture of interferon alpha-2B and Ribavirin is a negative number, indicating that there is a small amount of antagonism between these two drugs.
- Ribavirin has an IC 50 of 145 ⁇ M. This result can be explained by recognizing that the Replicon Assay permits evaluation of high Ribavirin concentrations that would not be possible in human therapy due to in vivo cytotoxicity ( Chutaputti A. (2000) Adverse effects and other safety aspects of the hepatitis C antivirals. Journal of Gastroenterology and Hepatology, 15 Suppl:E156-63 ).
- Ribavirin cytotoxicity in the Replicon Assay is observed and measured in two ways. In both the XTT metabolic assay to determine replicon cell viability ( Roehm NW., Rodgers G. H., Hatfield S. M., Glasebrook A. L.
- VCN viable cell numbers
- the VCN is computed for each of the Replicon Assay sample wells, and then we divide the HCV Replicon RNA copy number for a specific well by the VCN for that well. Once computed, this ratio is used instead of the HCV copy number to compute inhibition ("Avg. Inh using ratio": Fig 14A ).
- the true anti-HCV activity of a compound in the Replicon Assay corrected for general cytotoxicity can he estimated by dividing the number of HCV replicon RNA molecules measured in each sample by the VCN, thus normalizing to the number of viable cells in each sample.
- Fig. 14A shows an estimate of true Ribavirin anti-HCV activity in the Replicon Assay ("Avg. Inh using ratio").
- the estimate of the IC 50 for Ribavirin is best calculated using this method.
- "Avg. Inh original” shows the uncorrected IC 50 for Ribavirin, which is approximately 80 ⁇ M, whereas the corrected IC 50 value calculated from the "Avg.
- cytotoxicity of these compounds has no significant effect on HCV RNA accumulation in the Replicon Assay within the precision of the assay because such cytotoxicity occurs only at HCV serine protease inhibitor concentrations significantly greater than those tested in the Replicon Assay.
- Combination therapy employing HCV serine protease inhibitors of the present invention possesses several major advantages over single drug therapy.
- HCV serine protease inhibitor such as CU at the IC 95 level could be combined with a dose of interferon alpha, for example at the IC 50 level, and the result would be much more effective therapy than could be achieved with the HCV serine protease inhibitor alone without the adverse side effects caused by high doses of interferon alpha.
- a second major benefit of combination therapy is that because the two drugs act independently, there is less chance of development of mutant HCV strains that resist treatment. Development of resistance is a major concern with RNA viruses like HCV. Because of their high rate of mutation, such viruses can rapidly adapt to environmental stresses.
- a third benefit of combination therapy may be reduced cost, due to the need for lower amounts of therapeutic agents required for effective treatment.
- Additional immunomodulators that can be employed in the methods disclosed herein include, for example, alpha interferon 2A, consensus interferon, tau interferon, interferon + Ribavirin (Rebatron), pegylated interferon, and promoters of interferon gene expression. It is fully anticipated that the anti-HCV activity of these compounds will be improved when used in combination with HCV serine protease inhibitors such as those disclosed herein.
- HCV serine protease inhibitors will also be active in vivo , and more importantly, be capable of eliciting synergistic activity when used in combination with interferons, immune system stimulators thereof, or other compounds having HCV antiviral activity that act by a mechanism other than inhibition of the HCV serine protease.
Abstract
Claims (27)
- Composition pharmaceutique comprenant une quantité pharmaceutiquement acceptable du composé de l'une quelconque des revendications 1 ou 2 et un support pharmaceutiquement acceptable.
- Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications 1 ou 2, un interféron ayant une activité anti-virus de l'hépatite C, et un support pharmaceutiquement acceptable.
- Composition pharmaceutique selon la revendication 4, comprenant en outre, un composé ayant une activité anti-virus de l'hépatite C, où ledit composé est autre qu'un interféron.
- Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications 1 ou 2, un composé ayant une activité anti-virus de l'hépatite C, et un support pharmaceutiquement acceptable, où ledit composé est autre qu'un interféron.
- Composition pharmaceutique selon la revendication 5, où ledit composé selon l'une quelconque des revendications 1 ou 2, ledit interféron et ledit composé ayant une activité anti-virus de l'hépatite C, sont chacun présents en une quantité choisie parmi le groupe consistant en une quantité pharmaceutiquement acceptable, une quantité pharmaceutiquement acceptable sous-clinique, et une combinaison de celles-ci.
- Composition pharmaceutique selon la revendication 7, où ledit interféron est choisi parmi le groupe consistant en l'interféron alpha 2B, l'interféron alpha pegylé, l'interféron consensus, l'interféron alpha 2A, l'interféron lymphoblastoïde, et l'interféron tau ; et ledit composé ayant une activité anti-virus de l'hépatite C est choisi parmi le groupe consistant en l'interleukine 2, l'interleukine 6, l'interleukine 12, un composé qui amplifie le développement d'une réponse par cellules T helper de type 1, un ARN double brin, un ARN double brin complexé à la tobramycine, l'imiquimod, la ribavirine, un inhibiteur de l'inosine 5'-monophosphate déshydrogénase, l'amantadine et la rimantadine.
- Utilisation d'un composé selon la revendication 1 ou 2, dans la préparation d'un médicament pour inhiber la protéase de HCV.
- Utilisation d'un composé selon la revendication 1 ou 2, dans la préparation d'un médicament pour traiter un patient souffrant d'une infection par le HCV ou d'états physiologiques reliés à l'infection.
- Utilisation d'un composé selon la revendication 1 ou 2, en combinaison avec une quantité pharmaceutiquement efficace d'un composé d'une autre thérapie anti-HCV, dans la préparation d'un médicament pour traiter un patient souffrant d'une infection par le HCV ou d'états physiologiques reliés à l'infection.
- Utilisation selon la revendication 11, où la thérapie anti-HCV est l'interféron ou l'interféron dérivatisé.
- Utilisation d'un composé selon la revendication 1 ou 2, en combinaison avec un interféron ayant une activité anti-virus de l'hépatite C, dans la préparation d'un médicament pour le traitement ou la prévention d'une infection par le virus de l'hépatite C d'un patient le nécessitant.
- Utilisation d'un composé selon la revendication 1 ou 2, en combinaison avec un composé ayant une activité anti-virus de l'hépatite C, dans la préparation d'un médicament pour le traitement ou la prévention d'une infection par le virus de l'hépatite C d'un patient le nécessitant, où le composé est autre qu'un interféron.
- Utilisation d'un composé selon la revendication 1 ou 2, en combinaison avec un interféron ayant une activité anti-virus de l'hépatite C et un composé ayant une activité anti-virus de l'hépatite C, dans la préparation d'un médicament pour le traitement ou la prévention d'une infection par le virus de l'hépatite C d'un patient le nécessitant, où le composé est autre qu'un interféron.
- Utilisation selon la revendication 15, où ledit composé selon l'une quelconque des revendications 1 ou 2, ledit interféron et ledit composé ayant une activité anti-virus de l'hépatite C, sont chacun présents en une quantité choisie parmi le groupe consistant en une quantité pharmaceutiquement acceptable, une quantité pharmaceutiquement acceptable sous-clinique, et une combinaison de celles-ci.
- Utilisation selon la revendication 16, où ledit interféron est choisi parmi le groupe consistant en l'interféron alpha 2B, l'interféron alpha pegylé, l'interféron consensus, l'interféron alpha 2A, l'interféron lymphoblastoïde, et l'interféron tau ; et ledit composé ayant une activité anti-virus de l'hépatite C est choisi parmi le groupe consistant en l'interleukine 2, l'interleukine 6, l'interleukine 12, un composé qui amplifie le développement d'une réponse par cellules T helper de type 1, un ARN double brin, un ARN double brin complexé à la tobramycine, l'imiquimod, la ribavirine, un inhibiteur de l'inosine 5'-monophosphate déshydrogénase, l'amantadine et la rimantadine.
- Utilisation d'un composé selon la revendication 1 ou 2 et d'un interféron ayant une activité anti-virus de l'hépatite C, dans la préparation d'un médicament pour inhiber la réplication du virus de l'hépatite C dans une cellule.
- Utilisation selon la revendication 18, comprenant en outre, la mise en contact de ladite cellule, avec un composé ayant une activité anti-virus de l'hépatite C, où le composé est autre qu'un interféron.
- Utilisation d'un composé selon la revendication 1 ou 2 et d'un composé ayant une activité anti-virus de l'hépatite C, où le composé est autre qu'un interféron, dans la préparation d'un médicament pour inhiber la réplication du virus de l'hépatite C dans une cellule.
- Utilisation selon la revendication 19, où ledit inhibiteur de protéase à sérine du virus de l'hépatite C, ledit interféron, et ledit composé ayant une activité anti-virus de l'hépatite C sont chacun présents en une quantité choisie parmi le groupe consistant en une quantité pharmaceutiquement acceptable, une quantité pharmaceutiquement acceptable sous-clinique, et une combinaison de celles-ci.
- Utilisation selon la revendication 21, où ledit interféron est choisi parmi le groupe consistant en l'interféron alpha 2B, l'interféron alpha pegylé, l'interféron consensus, l'interféron alpha 2A, l'interféron lymphoblastoïde, et l'interféron tau ; et ledit composé ayant une activité anti-virus de l'hépatite C est choisi parmi le groupe consistant en l'interleukine 2, l'interleukine 6, l'interleukine 12, un composé qui amplifie le développement d'une réponse par cellules T helper de type 1, un ARN double brin, un ARN double brin complexé à la tobramycine, l'imiquimod, la ribavirine, un inhibiteur de l'inosine 5'-monophosphate déshydrogénase, l'amantadine et la rimantadine.
- Kit ou assemblage pharmaceutique, comprenant une série de récipients séparés, où au moins un desdits récipients contient un inhibiteur de protéase à sérine du virus de l'hépatite C selon la revendication 1 ou 2 et au moins un autre desdits récipients contient un interféron ayant une activité anti-virus de l'hépatite C.
- Kit ou assemblage pharmaceutique, comprenant une série de récipients séparés, où au moins un desdits récipients contient un inhibiteur de protéase à sérine du virus de l'hépatite C selon la revendication 1 ou 2 et au moins un autre desdits récipients contient un composé ayant une activité anti-virus de l'hépatite C, ledit composé étant autre qu'un interféron.
- Kit ou assemblage pharmaceutique, comprenant une série de récipients séparés, où au moins un desdits récipients contient un inhibiteur de protéase à sérine du virus de l'hépatite C selon la revendication 1 ou 2 et au moins un autre desdits récipients contient un interféron ayant une activité anti-virus de l'hépatite C, et au moins un autre desdits récipients contient un composé ayant une activité anti-virus de l'hépatite C, ledit composé étant autre qu'un interféron.
- Kit ou assemblage pharmaceutique selon la revendication 25, où ledit inhibiteur de protéase à sérine du virus de l'hépatite C, ledit interféron, et ledit composé ayant une activité anti-virus de l'hépatite C sont chacun présents en une quantité choisie parmi le groupe consistant en une quantité pharmaceutiquement acceptable, une quantité pharmaceutiquement acceptable sous-clinique, et une combinaison de celles-ci.
- Kit ou assemblage pharmaceutique selon la revendication 26, où ledit interféron est choisi parmi le groupe consistant en l'interféron alpha 2B, l'interféron alpha pegylé, l'interféron consensus, l'interféron alpha 2A, l'interféron lymphoblastoïde, et l'interféron tau ; et ledit composé ayant une activité anti-virus de l'hépatite C est choisi parmi le groupe consistant en l'interleukine 2, l'interleukine 6, l'interleukine 12, un composé qui amplifie le développement d'une réponse par cellules T helper de type 1, un ARN double brin, un ARN double brin complexé à la tobramycine, l'imiquimod, la ribavirine, un inhibiteur de l'inosine 5'-monophosphate déshydrogénase, l'amantadine et la rimantadine.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07012484A EP1876173A1 (fr) | 2000-08-31 | 2001-08-31 | Intermédiaires chiraux pour la préparation des Inhibiteurs de protéase peptidomimétique |
EP20100185155 EP2368901A1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de protéase peptidomimétique |
EP07012485A EP1878720B1 (fr) | 2000-08-31 | 2001-08-31 | Procédé pour la préparation des bicycloprolinates chiraux utiles en tant qu'intermediaires pour la préparation des inhibiteurs de protéase peptidominétique |
EP10185148A EP2368878A1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de protéase peptidomimétique |
EP10185132.7A EP2368877B1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de protéase peptidomimétique et des intermediaires chiraux pour le traitement des infections HCV |
EP07111000A EP1849797A3 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs peptidomimétiques de protease |
DK07012485.4T DK1878720T3 (da) | 2000-08-31 | 2001-08-31 | Fremgangsmåde til frembringelse af chirale bicycloprolinater som intermediat til frembringelsen af peptidomimetiske protease-inhibitorer |
SI200130924T SI1320540T1 (sl) | 2000-08-31 | 2001-08-31 | Peptidomimetiäśni proteazni ihibitor |
EP07012483.9A EP1958956B1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de prothèse peptidominétique |
EP10185722A EP2371839A1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de prothèse peptidominétique |
CY20091100765T CY1109216T1 (el) | 2000-08-31 | 2009-07-20 | Πεπτιδομιμητικοι αναστολεις πρωτεασης |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22939800P | 2000-08-31 | 2000-08-31 | |
US229398P | 2000-08-31 | ||
US27764101P | 2001-03-21 | 2001-03-21 | |
US277641P | 2001-03-21 | ||
PCT/US2001/026008 WO2002018369A2 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs peptidomimetiques de protease |
Related Child Applications (14)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07012483.9A Division EP1958956B1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de prothèse peptidominétique |
EP07111000A Division EP1849797A3 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs peptidomimétiques de protease |
EP07012485A Division EP1878720B1 (fr) | 2000-08-31 | 2001-08-31 | Procédé pour la préparation des bicycloprolinates chiraux utiles en tant qu'intermediaires pour la préparation des inhibiteurs de protéase peptidominétique |
EP10185132.7A Division EP2368877B1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de protéase peptidomimétique et des intermediaires chiraux pour le traitement des infections HCV |
EP07012484A Division EP1876173A1 (fr) | 2000-08-31 | 2001-08-31 | Intermédiaires chiraux pour la préparation des Inhibiteurs de protéase peptidomimétique |
EP07111000.1 Division-Into | 2007-06-25 | ||
EP07012485.4 Division-Into | 2007-06-26 | ||
EP07012484.7 Division-Into | 2007-06-26 | ||
EP07012483.9 Division-Into | 2007-06-26 | ||
EP10185148.3 Division-Into | 2010-10-01 | ||
EP10185132.7 Division-Into | 2010-10-01 | ||
EP10185155.8 Division-Into | 2010-10-01 | ||
EP10185722.5 Division-Into | 2010-10-01 | ||
EP10185745.6 Division-Into | 2010-10-01 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1320540A2 EP1320540A2 (fr) | 2003-06-25 |
EP1320540B1 EP1320540B1 (fr) | 2009-05-13 |
EP1320540B9 true EP1320540B9 (fr) | 2012-03-21 |
Family
ID=26923261
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10185132.7A Expired - Lifetime EP2368877B1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de protéase peptidomimétique et des intermediaires chiraux pour le traitement des infections HCV |
EP07111000A Withdrawn EP1849797A3 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs peptidomimétiques de protease |
EP07012483.9A Expired - Lifetime EP1958956B1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de prothèse peptidominétique |
EP10185722A Withdrawn EP2371839A1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de prothèse peptidominétique |
EP20100185155 Withdrawn EP2368901A1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de protéase peptidomimétique |
EP10185148A Withdrawn EP2368878A1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de protéase peptidomimétique |
EP01968040A Expired - Lifetime EP1320540B9 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs peptidomimetiques de protease |
EP07012485A Expired - Lifetime EP1878720B1 (fr) | 2000-08-31 | 2001-08-31 | Procédé pour la préparation des bicycloprolinates chiraux utiles en tant qu'intermediaires pour la préparation des inhibiteurs de protéase peptidominétique |
EP07012484A Withdrawn EP1876173A1 (fr) | 2000-08-31 | 2001-08-31 | Intermédiaires chiraux pour la préparation des Inhibiteurs de protéase peptidomimétique |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10185132.7A Expired - Lifetime EP2368877B1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de protéase peptidomimétique et des intermediaires chiraux pour le traitement des infections HCV |
EP07111000A Withdrawn EP1849797A3 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs peptidomimétiques de protease |
EP07012483.9A Expired - Lifetime EP1958956B1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de prothèse peptidominétique |
EP10185722A Withdrawn EP2371839A1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de prothèse peptidominétique |
EP20100185155 Withdrawn EP2368901A1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de protéase peptidomimétique |
EP10185148A Withdrawn EP2368878A1 (fr) | 2000-08-31 | 2001-08-31 | Inhibiteurs de protéase peptidomimétique |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07012485A Expired - Lifetime EP1878720B1 (fr) | 2000-08-31 | 2001-08-31 | Procédé pour la préparation des bicycloprolinates chiraux utiles en tant qu'intermediaires pour la préparation des inhibiteurs de protéase peptidominétique |
EP07012484A Withdrawn EP1876173A1 (fr) | 2000-08-31 | 2001-08-31 | Intermédiaires chiraux pour la préparation des Inhibiteurs de protéase peptidomimétique |
Country Status (37)
Country | Link |
---|---|
US (5) | US7820671B2 (fr) |
EP (9) | EP2368877B1 (fr) |
JP (4) | JP4689938B2 (fr) |
KR (10) | KR100968295B1 (fr) |
CN (7) | CN101693672B (fr) |
AR (1) | AR030591A1 (fr) |
AT (2) | ATE483686T1 (fr) |
AU (2) | AU8831801A (fr) |
BR (1) | BR0113666A (fr) |
CA (2) | CA2419607C (fr) |
CL (1) | CL2010000330A1 (fr) |
CY (2) | CY1109216T1 (fr) |
CZ (1) | CZ2003595A3 (fr) |
DE (4) | DE60143233D1 (fr) |
DK (2) | DK1320540T5 (fr) |
DZ (1) | DZ3438A1 (fr) |
EA (2) | EA017556B1 (fr) |
EC (2) | ECSP034493A (fr) |
ES (4) | ES2325481T3 (fr) |
HK (3) | HK1057758A1 (fr) |
HR (1) | HRP20030139B8 (fr) |
HU (1) | HUP0300855A3 (fr) |
IL (6) | IL154671A0 (fr) |
LU (1) | LU91960I2 (fr) |
MX (1) | MXPA03001780A (fr) |
NO (4) | NO329929B1 (fr) |
NZ (2) | NZ569670A (fr) |
PE (1) | PE20020474A1 (fr) |
PL (1) | PL211019B1 (fr) |
PT (1) | PT1320540E (fr) |
SI (1) | SI1320540T1 (fr) |
SK (1) | SK2492003A3 (fr) |
SV (1) | SV2003000617A (fr) |
TW (6) | TWI319763B (fr) |
UA (2) | UA81600C2 (fr) |
WO (1) | WO2002018369A2 (fr) |
ZA (1) | ZA200301641B (fr) |
Families Citing this family (237)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2409985A3 (fr) * | 1996-10-18 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de protéases, spécialement de la protéase ns3 du virus de l'hépatite c |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
WO2001074768A2 (fr) * | 2000-04-03 | 2001-10-11 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
KR20080021797A (ko) | 2000-05-26 | 2008-03-07 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
PE20020266A1 (es) | 2000-07-21 | 2002-05-11 | Schering Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c |
WO2002008244A2 (fr) | 2000-07-21 | 2002-01-31 | Schering Corporation | Nouveau peptide sous forme d'inhibiteurs de protease a serine ns3 d'hepatite virale c |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
GB2368339B (en) | 2000-10-26 | 2002-09-18 | Yissum Res Dev Co | Complex incorporating a plurality of antioxidants |
WO2003035060A1 (fr) * | 2001-10-24 | 2003-05-01 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la serine protease, en particulier de la protease ns3-ns4a du virus de l'hepatite c, integrant un systeme de cycles accoles |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
KR20040099425A (ko) | 2002-04-11 | 2004-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 c형 간염 바이러스 ns3-ns4프로테아제의 억제제 |
AU2003299519A1 (en) * | 2002-05-20 | 2004-05-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
DE14169110T1 (de) | 2002-06-28 | 2022-05-12 | Centre National De La Recherche Scientifique -Cnrs- | Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
AU2003277891A1 (en) * | 2002-09-23 | 2004-04-08 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
EP1594459B1 (fr) | 2002-12-30 | 2010-02-17 | Angiotech International Ag | Liberation de medicaments a partir d'une composition polymere a gelification rapide |
AU2011203054B2 (en) * | 2003-04-11 | 2012-04-26 | Vertex Pharmaceuticals, Incorporated | Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease |
EP2332935A1 (fr) * | 2003-04-11 | 2011-06-15 | Vertex Pharmaceuticals Incorporated | Inhibiteurs des serine proteases, en particulier de la protease NS3-NS4A du VHC |
AU2004240704B9 (en) | 2003-05-21 | 2009-10-22 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
SI3521297T1 (sl) | 2003-05-30 | 2022-04-29 | Gilead Pharmasset Llc | Modificirani fluorirani nukleozidni analogi |
CN101724022A (zh) | 2003-07-18 | 2010-06-09 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂 |
UY28500A1 (es) * | 2003-09-05 | 2005-04-29 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. |
US20050120398A1 (en) * | 2003-09-12 | 2005-06-02 | Vertex Pharmaceuticals Incorporated | Animal model for HCV infection |
TW200526686A (en) | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US7365092B2 (en) * | 2003-10-10 | 2008-04-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
CN1906208B (zh) * | 2003-10-10 | 2011-03-30 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
WO2005037860A2 (fr) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv |
EP1944042A1 (fr) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinaisons pour le traitement HCV |
CN1893978A (zh) * | 2003-10-27 | 2007-01-10 | 沃泰克斯药物股份有限公司 | 用于hcv治疗的组合 |
CA2551074A1 (fr) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Mutants resistant a la protease hcv ns3-ns4a |
WO2005043118A2 (fr) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Methode de decouverte de medicament |
TW200518746A (en) * | 2003-12-11 | 2005-06-16 | Schering Corp | Novel inhibitors of hepatitis C virus NS3/NS4A serine protease |
JP4682155B2 (ja) | 2004-01-21 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ウイルスに対して活性な大環状ペプチド |
EP1711515A2 (fr) | 2004-02-04 | 2006-10-18 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a |
AU2005219824B2 (en) * | 2004-02-27 | 2007-11-29 | Merck Sharp & Dohme Corp. | Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
AR048413A1 (es) * | 2004-02-27 | 2006-04-26 | Schering Corp | Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c |
KR20130018418A (ko) * | 2004-02-27 | 2013-02-21 | 머크 샤프 앤드 돔 코포레이션 | C형 간염 바이러스 ns3 세린 프로테아제의 억제제로서의 황 화합물 |
JP4745327B2 (ja) | 2004-02-27 | 2011-08-10 | シェーリング コーポレイション | C型肝炎ウイルスns3プロテアーゼのインヒビター |
KR101370580B1 (ko) * | 2004-06-08 | 2014-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 약학 조성물 |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
EP1771454B1 (fr) | 2004-07-20 | 2011-06-15 | Boehringer Ingelheim International GmbH | Analogues peptidiques inhibiteurs de l'hepatite c |
BRPI0516825A (pt) * | 2004-10-01 | 2008-09-23 | Vertex Pharma | inibição da protease ns3-ns4a do vìrus da hepatite c (vhc) |
MY141025A (en) * | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
ES2400582T3 (es) | 2005-03-21 | 2013-04-10 | Virobay, Inc. | Compuestos de alfa cetoamida como inhibidores de cisteína proteasa |
US20070015803A1 (en) * | 2005-04-12 | 2007-01-18 | Romark Laboratories L.C. | Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
JP5030947B2 (ja) | 2005-05-13 | 2012-09-19 | ヴァイロケム・ファーマ・インコーポレーテッド | フラビウイルス感染の治療及び予防のための化合物及び方法 |
NZ563361A (en) | 2005-06-02 | 2011-02-25 | Schering Corp | HCV protease inhibitors in combination with food |
PE20070011A1 (es) | 2005-06-02 | 2007-03-08 | Schering Corp | Formulaciones farmaceuticas de compuestos inhibidores de proteasa del vhc o catepsina |
US20060276404A1 (en) * | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
US20070004635A1 (en) * | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
US8012939B2 (en) | 2005-07-29 | 2011-09-06 | Tibotec Pharmaceuticals Ltd. Co | Macrocyclic inhibitors of hepatitis C virus |
WO2007014924A1 (fr) | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Inhibiteurs macrocycliques du virus de l'hépatite c |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
DE602006019883D1 (de) | 2005-07-29 | 2011-03-10 | Medivir Ab | Makrocyclische inhibitoren des hepatitis-c-virus |
PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
PL1912997T3 (pl) | 2005-07-29 | 2012-02-29 | Tibotec Pharm Ltd | Makrocykliczne inhibitory wirusa zapalenia wątroby typu C |
EP1919899B1 (fr) | 2005-07-29 | 2011-01-19 | Tibotec Pharmaceuticals | Inhibiteurs macrocycliques du virus de l'hépatite c |
JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
JP2009505966A (ja) * | 2005-08-02 | 2009-02-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼのインヒビター |
EP2194043B1 (fr) * | 2005-08-19 | 2013-12-25 | Vertex Pharmaceuticals Incorporated | Procédés |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
EP2392588A3 (fr) | 2005-11-11 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Variantes du virus de l'hépatite C |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
ATE509941T1 (de) * | 2006-01-11 | 2011-06-15 | Seikagaku Kogyo Co Ltd | Cycloalkylcarbonylaminosäureester-derivat und herstellungsverfahren dafür |
JP3975226B2 (ja) * | 2006-01-11 | 2007-09-12 | 生化学工業株式会社 | シクロアルキルカルボニルアミノ酸誘導体及びその製造方法 |
JP4047365B2 (ja) * | 2006-01-11 | 2008-02-13 | 生化学工業株式会社 | シクロアルカンカルボキサミド誘導体及びその製造方法 |
WO2007083620A1 (fr) * | 2006-01-20 | 2007-07-26 | Kaneka Corporation | PROCÉDÉ DE PRODUCTION D'UN DÉRIVÉ DE β-AMINO-α-HYDROXYACIDE DE TYPE AMIDE |
CN101489557B (zh) * | 2006-02-27 | 2013-12-18 | 弗特克斯药品有限公司 | 包含vx-950的共晶体和包含所述共晶体的药物组合物 |
JP5646814B2 (ja) * | 2006-03-06 | 2014-12-24 | アッヴィ・インコーポレイテッド | Hcvを治療するためのリトナビルの組成物及び使用方法 |
EP2194039A1 (fr) * | 2006-03-16 | 2010-06-09 | Vertex Pharmceuticals Incorporated | Procédé de préparation de composés optiquement actifs |
BRPI0709568A2 (pt) * | 2006-03-16 | 2011-07-12 | Vertex Pharmaceuticals Incorporarted | processos e intermediários para preparar compostos estéricos |
KR20090025187A (ko) * | 2006-03-20 | 2009-03-10 | 버텍스 파마슈티칼스 인코포레이티드 | 의약 조성물 |
EP1998759A2 (fr) * | 2006-03-23 | 2008-12-10 | Schering Corporation | Combinaisons d'un ou plusieurs inhibiteurs de la protease du vhc et d'un ou plusieurs inhibiteurs de cyp3a4, et methodes de traitement associees |
WO2007120595A2 (fr) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Composés organiques et leurs utilisations |
MX2008013119A (es) | 2006-04-11 | 2008-10-21 | Novartis Ag | Inhibidores de hcv/vih y sus usos. |
CA2651762A1 (fr) | 2006-05-23 | 2007-11-29 | Irm Llc | Composes et compositions en tant qu'inhibiteurs de proteases activatrices de canal |
DE102006059317A1 (de) | 2006-07-04 | 2008-01-10 | Evonik Degussa Gmbh | Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden |
EP1886685A1 (fr) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X |
US20120220520A1 (en) * | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
EP2559692A1 (fr) | 2006-11-15 | 2013-02-20 | Virochem Pharma Inc. | Analogues du thiophène pour le traitement ou la prévention d'infections par un flavivirus |
EA200970493A1 (ru) | 2006-11-17 | 2009-10-30 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
EP2428204A3 (fr) | 2006-12-07 | 2012-07-04 | Schering Corporation | Formulation de matrice sensible au pH |
WO2008074035A1 (fr) | 2006-12-27 | 2008-06-19 | Abbott Laboratories | Inhibiteurs de protéase du vhc et utilisations de ceux-ci |
WO2008095058A1 (fr) * | 2007-02-01 | 2008-08-07 | Taigen Biotechnology Co. Ltd. | Inhibiteurs de la protéase du virus de l'hépatite c |
US8937080B2 (en) | 2007-02-08 | 2015-01-20 | Medivir Ab | Pyrimidine substituted macrocyclic HCV inhibitors |
JP2010518099A (ja) | 2007-02-09 | 2010-05-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
EP2463285A1 (fr) | 2007-02-27 | 2012-06-13 | Vertex Pharmaceuticals Inc. | Co-cristaux et compositions pharmaceutiques les comprenant |
MX2009009176A (es) | 2007-02-27 | 2009-09-28 | Vertex Pharma | Inhibidores de serina-proteasas. |
WO2008127613A1 (fr) * | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | Compositions pharmaceutiques inédites |
AU2008248116A1 (en) | 2007-05-04 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
CN101827589B (zh) * | 2007-08-03 | 2016-08-17 | 拜伊特朗有限公司 | 抗丙型肝炎病毒的组合物及方法 |
CA2704284A1 (fr) | 2007-08-30 | 2009-03-12 | Vertex Pharmaceuticals Incorporated | Co-cristaux et compositions pharmaceutiques les comportant |
AU2008301981A1 (en) | 2007-09-14 | 2009-03-26 | Merck Sharp & Dohme Corp. | Method of treating hepatitis C patients |
US20090082366A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
EA020951B1 (ru) * | 2007-10-10 | 2015-03-31 | Новартис Аг | Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека) |
US8106059B2 (en) | 2007-10-24 | 2012-01-31 | Virobay, Inc. | Substituted pyrazines that inhibit protease cathepsin S and HCV replication |
US20090111757A1 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
EP2238142B1 (fr) | 2007-12-24 | 2012-07-04 | Janssen R&D Ireland | Indoles macrocycliques en tant qu'inhibiteurs du virus de l'hépatite c |
DE102008009761A1 (de) | 2008-02-19 | 2009-08-27 | Bayer Materialscience Ag | Verfahren zur Herstellung von Isocyanaten |
EP2101173A1 (fr) | 2008-03-14 | 2009-09-16 | Vivalis | Procédé in vitro pour déterminer si un candidat destiné à un médicament pour une protéine cible est actif contre une variante de cette protéine |
CN101580535B (zh) * | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | 丙型肝炎病毒蛋白酶抑制剂 |
EP2481737A1 (fr) | 2008-06-24 | 2012-08-01 | Merck Sharp & Dohme Corp. | Procédés biocatalytiques permettant la préparation de composés de proline bicycliques fusionnés sensiblement stéréomériquement |
US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
WO2010014744A1 (fr) * | 2008-07-29 | 2010-02-04 | The Scripps Research Institute | Inhibiteurs d'une infection par le virus de l'hépatite c |
US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
JP5762971B2 (ja) | 2008-12-03 | 2015-08-12 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Hcvns5aの阻害剤 |
CA2745119A1 (fr) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hepatite c de type ns5a |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
WO2010093843A2 (fr) | 2009-02-12 | 2010-08-19 | Vertex Pharmaceuticals Incorporated | Polythérapies contre le hcv |
AU2010229795A1 (en) | 2009-03-27 | 2011-10-13 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
AR077138A1 (es) | 2009-06-23 | 2011-08-03 | Gilead Sciences Inc | Composiciones farmaceuticas utiles para tratar el vhc |
PL2477980T3 (pl) | 2009-09-15 | 2017-02-28 | Taigen Biotechnology Co., Ltd. | Inhibitory proteazy hcv |
TWI404269B (zh) * | 2009-09-18 | 2013-08-01 | Advanced Connectek Inc | High speed plug connector |
UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
AU2010326225A1 (en) | 2009-11-25 | 2012-06-07 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
MX2012006877A (es) * | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
AU2010336355A1 (en) | 2009-12-24 | 2012-07-05 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
KR101781789B1 (ko) | 2010-01-27 | 2017-09-26 | 에이비 파르마 리미티드. | C형 간염 바이러스 억제제로 사용되는 다환 헤테로사이클릭 화합물 |
AU2011210795A1 (en) | 2010-01-29 | 2012-08-02 | Vertex Pharmaceuticals Incorporated | Therapies for treating Hepatitis C virus infection |
WO2011112516A1 (fr) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Traitement et prévention de l'infection par le virus de l'hépatite c en utilisant des oligonucléotides antisens de la kinase c-raf |
CN103038237A (zh) | 2010-03-24 | 2013-04-10 | 沃泰克斯药物股份有限公司 | 用于黄病毒感染治疗或预防的类似物 |
AU2011232331A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
EP2550268A1 (fr) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues pour traiter ou prévenir les infections à flavivirus |
WO2011119858A1 (fr) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues destinés au traitement ou à la prévention d'infections à flavivirus |
TWI515000B (zh) | 2010-04-01 | 2016-01-01 | 伊迪尼克製藥公司 | 用於治療病毒感染之化合物及醫藥組合物 |
EP2575866A4 (fr) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | Inhibiteurs de ns5a du vhc |
CN103108865A (zh) | 2010-06-03 | 2013-05-15 | 弗特克斯药品有限公司 | 方法和中间体 |
WO2011156545A1 (fr) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Modèle dynamique viral pour une polythérapie contre le vhc |
EP2582717A2 (fr) | 2010-06-15 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Mutants de la protéase ns5b du vhc |
UY33473A (es) | 2010-06-28 | 2012-01-31 | Vertex Pharma | Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus |
EP2585448A1 (fr) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Composés et méthodes de traitement ou de prévention d'infections à flavovirus |
WO2012006070A1 (fr) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Composés et méthodes de traitement ou de prévention d'infections à flavivirus |
TW201208704A (en) | 2010-07-14 | 2012-03-01 | Vertex Pharma | Palatable pharmaceutical composition |
AR082619A1 (es) | 2010-08-13 | 2012-12-19 | Hoffmann La Roche | Inhibidores del virus de la hepatitis c |
CA2808291A1 (fr) | 2010-08-17 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Composes et methodes de traitement ou de prevention d'infections virales par des flaviviridae |
KR20130110170A (ko) | 2010-09-22 | 2013-10-08 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오타이드 유사체 |
MX2013003945A (es) | 2010-10-08 | 2013-06-05 | Novartis Ag | Formulaciones de vitamina e como inhibidoras de sulfamida ns3. |
CA2815416A1 (fr) | 2010-10-21 | 2012-04-26 | Vertex Pharmaceuticals Incorporated | Biomarqueurs pour des patients infectes par le vhc |
EA025151B1 (ru) | 2010-10-26 | 2016-11-30 | Пресидио Фармасьютикалс, Инк. | Ингибиторы вируса гепатита с |
WO2012107589A1 (fr) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc |
WO2012109646A1 (fr) | 2011-02-11 | 2012-08-16 | Vertex Pharmaceuticals Incorporated | Traitement du vhc chez des patients infectés par le vih |
WO2012123298A1 (fr) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Composés antiviraux |
JP2014514295A (ja) | 2011-03-31 | 2014-06-19 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
US8680152B2 (en) | 2011-05-02 | 2014-03-25 | Virobay, Inc. | Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain |
WO2012158513A1 (fr) | 2011-05-13 | 2012-11-22 | Vertex Pharmaceuticals Incorporated | Procédés et intermédiaires |
CA2857705A1 (fr) | 2011-06-16 | 2012-12-20 | AB Pharma Ltd. | Compose heterocyclique macrocyclique pour l'inhibition du virus de l'hepatite c, sa preparation et ses applications |
WO2012175700A1 (fr) | 2011-06-23 | 2012-12-27 | Digna Biotech, S. L. | Traitement de l'hépatite c chronique avec ifn-a5 en combinaison avec ifn-a2b dans une cohorte de patients |
US20120328565A1 (en) | 2011-06-24 | 2012-12-27 | Brinkman John A | Antiviral compounds |
TW201317223A (zh) | 2011-07-26 | 2013-05-01 | Vertex Pharma | 噻吩化合物 |
WO2013016499A1 (fr) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Procédés de préparation de composés du thiophène |
EP2755985B1 (fr) | 2011-09-12 | 2017-11-01 | Idenix Pharmaceuticals LLC | Composés et compositions pharmaceutiques pour le traitement d'infections virales |
US9474759B2 (en) | 2011-09-27 | 2016-10-25 | Kansas State University Research Foundation | Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses |
BR112014008616A2 (pt) | 2011-10-10 | 2017-04-18 | Hoffmann La Roche | compostos antivirais |
EP2766347B1 (fr) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Composés de tétrahydroisoquinoléine substitués en tant qu'inhibiteurs du facteur xia |
US9108951B2 (en) | 2011-10-14 | 2015-08-18 | Bristol-Myers Squibb Company | Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors |
PE20141825A1 (es) | 2011-10-14 | 2014-11-29 | Bristol Myers Squibb Co | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia |
US8466159B2 (en) * | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
DK2583677T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
CA2811250C (fr) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methodes de traitement du vhc |
BR112014013972A2 (pt) | 2011-12-16 | 2017-06-13 | Hoffmann La Roche | inibidores de hcv nssa |
RS56212B1 (sr) | 2011-12-20 | 2017-11-30 | Riboscience Llc | 2',4'-difluoro-2'-metilom supstituisani nukleozidni derivati kao inhibitori replikacije rna hcv-a |
CN104011060A (zh) | 2011-12-20 | 2014-08-27 | 弗·哈夫曼-拉罗切有限公司 | 作为hcv rna复制抑制剂的4‘-叠氮基,3’-氟取代的核苷衍生物 |
ES2558608T3 (es) | 2011-12-28 | 2016-02-05 | Janssen Sciences Ireland Uc | Derivados hetero-bicíclicos como inhibidores del VHC |
WO2013116339A1 (fr) | 2012-01-31 | 2013-08-08 | Vertex Pharmaceuticals Incorporated | Formulations très puissantes de vx-950 |
ITMI20120192A1 (it) | 2012-02-13 | 2013-08-14 | Dipharma Francis Srl | Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi |
CN104254518A (zh) * | 2012-02-16 | 2014-12-31 | 阿奇克斯制药公司 | 线性肽抗生素 |
CN104185624B (zh) | 2012-02-24 | 2016-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒化合物 |
ITMI20120359A1 (it) | 2012-03-07 | 2013-09-08 | Dipharma Francis Srl | Procedimento per la preparazione di intermedi utili nella preparazione di un inibitore delle proteasi virali |
ITMI20120391A1 (it) * | 2012-03-13 | 2013-09-14 | Dipharma Francis Srl | Procedimento per la sintesi di un intermedio ciclopropilammidico utile nella preparazione di un inibitore delle proteasi virali |
WO2013136265A1 (fr) | 2012-03-13 | 2013-09-19 | Dipharma Francis S.R.L. | Synthèse d'un intermédiaire d'un composé antiviral |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
WO2013166319A1 (fr) | 2012-05-02 | 2013-11-07 | Kansas State University Research Foundation | Composés macrocycliques et peptidomimétiques en tant qu'antiviraux à large spectre contre des protéases 3c ou de type 3c de picornavirus, calicivirus et coronavirus |
ITMI20120800A1 (it) * | 2012-05-10 | 2013-11-11 | Dipharma Francis Srl | Procedimento per la preparazione di un intermedio utile nella preparazione di un inibitore delle proteasi virali |
CN103450066B (zh) * | 2012-05-30 | 2017-03-15 | 博瑞生物医药(苏州)股份有限公司 | 特拉匹韦中间体的制备方法 |
WO2013178682A2 (fr) | 2012-05-30 | 2013-12-05 | Chemo Ibérica, S.A. | Procédé à multicomposants pour la préparation de composés bicycliques |
US20140010783A1 (en) | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
WO2014015217A1 (fr) | 2012-07-19 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Biomarqueurs pour patients infectés par le hcv |
WO2014033667A1 (fr) | 2012-08-30 | 2014-03-06 | Ranbaxy Laboratories Limited | Procédé pour la préparation de télaprévir |
WO2014045263A2 (fr) * | 2012-09-24 | 2014-03-27 | Dr. Reddy's Laboratories Limited | Procédé de préparation d'intermédiaires du télaprévir |
WO2014059214A1 (fr) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Composés de tétrahydroisoquinoléine à substitution guanidine et amine utilisés comme inhibiteurs du facteur xia |
US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
WO2014059203A1 (fr) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Formes cristallines d'un inhibiteur de facteur xia |
EP2912047B1 (fr) | 2012-10-29 | 2016-08-24 | Cipla Limited | Analogues de phosphonate antiviraux et leur procédé de préparation |
ITMI20122036A1 (it) | 2012-11-29 | 2014-05-30 | Dipharma Francis Srl | Sintesi di un intermedio di un composto antivirale |
WO2014096374A1 (fr) | 2012-12-21 | 2014-06-26 | Sandoz Ag | Procédé de synthèse de pyrrolidines et de pyrroles |
CA2892589A1 (fr) | 2013-01-23 | 2014-07-31 | F. Hoffmann-La Roche Ag | Derives de triazole antiviraux |
CN103113288B (zh) * | 2013-02-04 | 2015-05-20 | 苏州永健生物医药有限公司 | 一种八氢环戊烯并[c]吡咯羧酸衍生物的合成方法 |
WO2014134251A1 (fr) | 2013-02-28 | 2014-09-04 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques |
JP6018715B2 (ja) | 2013-03-05 | 2016-11-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗ウイルス化合物 |
ES2712699T3 (es) | 2013-03-25 | 2019-05-14 | Bristol Myers Squibb Co | Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa |
ITMI20130706A1 (it) | 2013-04-30 | 2014-10-31 | Dipharma Francis Srl | Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi |
MX2015015781A (es) | 2013-05-16 | 2016-06-02 | Riboscience Llc | Derivados de nucleósido 4'-azido, 3'-deoxi-3'-fluoro sustituido. |
WO2014186637A1 (fr) | 2013-05-16 | 2014-11-20 | Riboscience Llc | Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués |
US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
CN104163851B (zh) * | 2013-05-20 | 2019-03-05 | 湘北威尔曼制药股份有限公司 | 氟代的α-羰基类HCV NS3/4A丝氨酸蛋白酶抑制剂 |
CN103288671B (zh) * | 2013-06-20 | 2014-10-29 | 上海步越化工科技有限公司 | 一种(3s)-3-氨基-n-环丙基-2-羟基己酰胺盐酸盐的合成方法 |
WO2014203208A1 (fr) | 2013-06-21 | 2014-12-24 | Ranbaxy Laboratories Limited | Procédé pour la préparation de télaprévir et d'intermédiaires de télaprévir |
WO2014203224A1 (fr) | 2013-06-21 | 2014-12-24 | Ranbaxy Laboratories Limited | Procédé pour la préparation de télaprévir et d'intermédiaires de télaprévir |
CN104292146B (zh) * | 2013-06-24 | 2017-04-26 | 上海医药工业研究院 | 特拉匹韦中间体及其制备方法 |
CN104558106B (zh) * | 2013-10-19 | 2019-12-10 | 广东东阳光药业有限公司 | 一种治疗丙肝药物的制备方法 |
CN104610272B (zh) * | 2013-11-05 | 2017-03-29 | 上海唐润医药科技有限公司 | 环状黄酮或异黄酮类化合物及其用途 |
EP2899207A1 (fr) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | Nouveau procédé pour tester l'inhibition de la protéase du HCV |
CN116987080A (zh) | 2014-01-31 | 2023-11-03 | 百时美施贵宝公司 | 作为因子xia抑制剂的具有杂环p2′基团的大环化合物 |
NO2760821T3 (fr) | 2014-01-31 | 2018-03-10 | ||
CN104926712B (zh) * | 2014-03-20 | 2018-03-23 | 上海医药工业研究院 | 合成特拉匹韦的中间体及其制备方法 |
CN104926831A (zh) * | 2014-03-20 | 2015-09-23 | 上海医药工业研究院 | 合成特拉匹韦的中间体及其制备方法 |
US10240427B2 (en) | 2014-07-07 | 2019-03-26 | Halliburton Energy Services, Inc. | Downhole tools comprising aqueous-degradable sealing elements |
JP6526796B2 (ja) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Fxia阻害剤であるジアミドマクロ環 |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
JP2019507176A (ja) | 2016-03-04 | 2019-03-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Htra1阻害剤としての新規ジフルオロケタミド誘導体 |
JP2019513698A (ja) | 2016-03-04 | 2019-05-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Htra1阻害剤としての新規なトリフルオロメチルプロパンアミド誘導体 |
EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
JP7076438B2 (ja) * | 2016-06-21 | 2022-05-27 | オリオン・オフサルモロジー・エルエルシー | 脂肪族プロリンアミド誘導体 |
CA3025253A1 (fr) | 2016-06-21 | 2017-12-28 | Orion Ophthalmology LLC | Derives heterocycliques de prolinamide |
US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
EP3504193A1 (fr) * | 2016-08-23 | 2019-07-03 | H. Hoffnabb-La Roche Ag | Nouveaux dérivés de difluorocétamide en tant qu'inhibiteurs de htra1 |
KR20200056420A (ko) | 2017-09-21 | 2020-05-22 | 리보사이언스 엘엘씨 | Hcv rna 복제의 억제제로서 4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체 |
CN109337537B (zh) * | 2018-09-26 | 2022-10-25 | 河北晨阳工贸集团有限公司 | 一种起重机专用单组分水性面漆及其制备方法 |
CN110668538B (zh) * | 2019-09-20 | 2021-10-22 | 济南大学 | 一种聚合氯化钛的制备方法 |
CN114057702B (zh) * | 2020-07-31 | 2022-09-30 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
CN115960088A (zh) * | 2020-07-31 | 2023-04-14 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
WO2023149981A1 (fr) * | 2022-02-07 | 2023-08-10 | Purdue Research Foundation | Composés pour le traitement du sars |
CN114703003B (zh) * | 2022-04-14 | 2023-04-28 | 上海绿晟环保科技有限公司 | 一种负载碳量子点的纳米材料润滑添加剂及其制备方法 |
CN115417790A (zh) * | 2022-10-09 | 2022-12-02 | 山东大学 | 一类新型偶氮类发泡剂及合成方法 |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3719667A (en) | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
DE3226768A1 (de) | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
DE3211676A1 (de) | 1982-03-30 | 1983-10-06 | Hoechst Ag | Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung |
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
FR2570695A1 (fr) * | 1984-09-27 | 1986-03-28 | Synthelabo | Diphenylazomethines a chaine ramifiee ou cyclique, leur preparation et leur application en therapeutique |
FR2575753B1 (fr) | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5496927A (en) | 1985-02-04 | 1996-03-05 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
DE3683541D1 (de) * | 1985-06-07 | 1992-03-05 | Ici America Inc | Selektionierte difluorverbindungen. |
US4835168A (en) | 1985-12-16 | 1989-05-30 | Eli Lilly And Company | Thiadiazole antiviral agents |
US5231084A (en) | 1986-03-27 | 1993-07-27 | Hoechst Aktiengesellschaft | Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons |
US5736520A (en) | 1988-10-07 | 1998-04-07 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
NZ235155A (en) | 1989-09-11 | 1993-04-28 | Merrell Dow Pharma | Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical |
US5371072A (en) * | 1992-10-16 | 1994-12-06 | Corvas International, Inc. | Asp-Pro-Arg α-keto-amide enzyme inhibitors |
EP0604182B1 (fr) | 1992-12-22 | 2000-10-11 | Eli Lilly And Company | Inhibiteurs de la protéase du VIH |
ES2189721T3 (es) | 1992-12-29 | 2003-07-16 | Abbott Lab | Inhibidores de proteasa retroviral. |
US5384410A (en) | 1993-03-24 | 1995-01-24 | The Du Pont Merck Pharmaceutical Company | Removal of boronic acid protecting groups by transesterification |
US5656600A (en) * | 1993-03-25 | 1997-08-12 | Corvas International, Inc. | α-ketoamide derivatives as inhibitors of thrombosis |
US5672582A (en) | 1993-04-30 | 1997-09-30 | Merck & Co., Inc. | Thrombin inhibitors |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
US5468858A (en) | 1993-10-28 | 1995-11-21 | The Board Of Regents Of Oklahoma State University Physical Sciences | N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents |
IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
HUT72440A (en) | 1994-03-31 | 1996-04-29 | Bristol Myers Squibb Co | Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them |
US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5861267A (en) * | 1995-05-01 | 1999-01-19 | Vertex Pharmaceuticals Incorporated | Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
JPH09124691A (ja) * | 1995-08-25 | 1997-05-13 | Green Cross Corp:The | ペプチド化合物およびそれを含有する医薬組成物 |
US6060469A (en) | 1995-11-23 | 2000-05-09 | Merck Sharp & Dohme Ltd. | Spiro-piperidine derivatives and their use as tachykinin antagonists |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
CA2252465C (fr) | 1996-04-23 | 2007-07-03 | Vertex Pharmaceuticals Incorporated | Derives d'uree agissant comme inhibiteurs de l'enzyme impdh |
US6127422A (en) | 1996-05-06 | 2000-10-03 | Eli Lilly And Company | Anti-viral method |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
JPH11513890A (ja) | 1996-05-10 | 1999-11-30 | シェーリング コーポレイション | C型肝炎ウイルスns3プロテアーゼの合成インヒビター |
AU3073297A (en) | 1996-05-17 | 1997-12-05 | Data Card Corporation | Curable topcoat composition and methods for use |
US6245919B1 (en) * | 1996-06-28 | 2001-06-12 | Haruhiko Shinozaki | Cyclopropylglycine derivatives and agonists for metabotronic L-glutamate receptors |
WO1998000391A1 (fr) * | 1996-06-28 | 1998-01-08 | Nippon Chemiphar Co., Ltd. | Derives de cyclopropylglycine et agoniste du recepteur du l-glutamate du type a regulation metabolique |
US6153579A (en) * | 1996-09-12 | 2000-11-28 | Vertex Pharmaceuticals, Incorporated | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
WO1998013369A1 (fr) | 1996-09-25 | 1998-04-02 | Merck Sharp & Dohme Limited | Derives spiro-azacycliques, preparation de ces derives et leur utilisation comme antagonistes de la tachykinine |
DE69725023T2 (de) | 1996-10-08 | 2004-08-05 | Colorado State University Research Foundation, Fort Collins | Katalytische asymmetrische epoxidierung |
EP2409985A3 (fr) * | 1996-10-18 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de protéases, spécialement de la protéase ns3 du virus de l'hépatite c |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
DE19648011A1 (de) | 1996-11-20 | 1998-05-28 | Bayer Ag | Cyclische Imine |
DK0966465T3 (da) | 1997-03-14 | 2003-10-20 | Vertex Pharma | Inhibitorer af IMPDH-enzymer |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
GB9708484D0 (en) | 1997-04-25 | 1997-06-18 | Merck Sharp & Dohme | Therapeutic agents |
GB9711114D0 (en) | 1997-05-29 | 1997-07-23 | Merck Sharp & Dohme | Therapeutic agents |
IL134232A0 (en) * | 1997-08-11 | 2001-04-30 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptides |
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
HUP0100100A3 (en) * | 1997-08-11 | 2001-12-28 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use |
US6183121B1 (en) * | 1997-08-14 | 2001-02-06 | Vertex Pharmaceuticals Inc. | Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets |
US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
US6211338B1 (en) | 1997-11-28 | 2001-04-03 | Schering Corporation | Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide |
WO1999050230A1 (fr) | 1998-03-31 | 1999-10-07 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de serine protease, particulierement de la protease ns3 du virus de l'hepatite c |
US6518305B1 (en) * | 1998-04-23 | 2003-02-11 | Abbott Laboratories | Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases |
US6251583B1 (en) | 1998-04-27 | 2001-06-26 | Schering Corporation | Peptide substrates for HCV NS3 protease assays |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AR022061A1 (es) * | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
DE19836514A1 (de) | 1998-08-12 | 2000-02-17 | Univ Stuttgart | Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette |
US6117639A (en) * | 1998-08-31 | 2000-09-12 | Vertex Pharmaceuticals Incorporated | Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity |
US6025516A (en) | 1998-10-14 | 2000-02-15 | Chiragene, Inc. | Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes |
EP1027885B1 (fr) | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Compositions de médicaments basiques avec une meilleure biodisponibilité |
US20020042046A1 (en) | 1999-02-25 | 2002-04-11 | Vertex Pharmaceuticals, Incorporated | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
CN1196687C (zh) | 1999-03-19 | 2005-04-13 | 沃泰克斯药物股份有限公司 | Impdh酶抑制剂 |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
US20020183249A1 (en) | 1999-08-31 | 2002-12-05 | Taylor Neil R. | Method of identifying inhibitors of CDC25 |
US6774212B2 (en) | 1999-12-03 | 2004-08-10 | Bristol-Myers Squibb Pharma Company | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease |
US6365380B2 (en) * | 2000-02-23 | 2002-04-02 | Pcbu Services, Inc. | Method for stereoselectively inverting a chiral center of a chemical compound using an enzyme and a metal catalyst |
EP1261611A2 (fr) | 2000-02-29 | 2002-12-04 | Bristol-Myers Squibb Pharma Company | Inhibiteurs de la prot ase ns3 du virus de l'h patite c |
WO2001074768A2 (fr) * | 2000-04-03 | 2001-10-11 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c |
RU2002129564A (ru) | 2000-04-05 | 2004-05-10 | Шеринг Корпорейшн (US) | Макроциклические ингибиторы сериновой ns3-протеазы, включающие n-циклические р2 структурные элементы вируса гепатита с |
CA2406532A1 (fr) | 2000-04-19 | 2001-11-01 | Schering Corporation | Inhibiteurs macrocycliques de la protease ns3-serine du virus de l'hepatite c comprenant des fractions p2 alkyle et aryle alanine |
EP1295876A4 (fr) | 2000-06-30 | 2005-10-19 | Amides d'acide carboxylique, azides et amino-alcools et procedes de preparation de alpha-ceto amides a l'aide de ces derniers | |
AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
AU2001277967A1 (en) | 2000-07-21 | 2002-02-05 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
WO2002008244A2 (fr) * | 2000-07-21 | 2002-01-31 | Schering Corporation | Nouveau peptide sous forme d'inhibiteurs de protease a serine ns3 d'hepatite virale c |
PE20020266A1 (es) | 2000-07-21 | 2002-05-11 | Schering Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US6939692B2 (en) | 2000-09-12 | 2005-09-06 | Degussa Ag | Nucleotide sequences coding for the pknB gene |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
HUP0500456A3 (en) | 2000-11-20 | 2012-05-02 | Bristol Myers Squibb Co | Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use |
AR031905A1 (es) | 2000-12-12 | 2003-10-08 | Schering Corp | Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c |
US6727366B2 (en) | 2000-12-13 | 2004-04-27 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors |
US6653295B2 (en) | 2000-12-13 | 2003-11-25 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
AU2002243791B2 (en) | 2001-01-22 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
WO2002061149A2 (fr) * | 2001-01-30 | 2002-08-08 | Vertex Pharmaceuticals Incorporated | Detection quantitative d'acides nucleiques |
GB0102342D0 (en) | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
ATE431396T1 (de) * | 2001-03-27 | 2009-05-15 | Vertex Pharma | Für hcv-infektion geeignete zusammensetzungen und verfahren |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
US7034178B2 (en) | 2001-07-03 | 2006-04-25 | Altana Pharma Ag | Process for the production of 3-phenylisoserine |
NZ530000A (en) * | 2001-07-11 | 2007-03-30 | Vertex Pharma | Peptidomimetic bridged bicyclic serine protease inhibitors |
US7029561B2 (en) | 2001-07-25 | 2006-04-18 | The United States Of America As Represented By The Secretary Of Commerce | Fluidic temperature gradient focusing |
JP2003055389A (ja) | 2001-08-09 | 2003-02-26 | Univ Tokyo | 錯体及びそれを用いたエポキシドの製法 |
US6824769B2 (en) * | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
WO2003035060A1 (fr) * | 2001-10-24 | 2003-05-01 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la serine protease, en particulier de la protease ns3-ns4a du virus de l'hepatite c, integrant un systeme de cycles accoles |
IL161970A0 (en) | 2001-11-14 | 2005-11-20 | Teva Pharma | Amorphous and crystalline forms of losartion potassium and process fortheir preparation |
CA2369711A1 (fr) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Peptides macrocycliques qui agissent contre le virus de l'hepatite c |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2369970A1 (fr) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Tri-peptides inhibiteur de l'hepatite c |
AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
KR20040099425A (ko) * | 2002-04-11 | 2004-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 c형 간염 바이러스 ns3-ns4프로테아제의 억제제 |
BR0313164A (pt) | 2002-08-01 | 2007-07-17 | Pharmasset Inc | compostos com o sistema biciclo[4.2.1] nonano para o tratamento de infecções por flaviviridae |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
CA2413705A1 (fr) | 2002-12-06 | 2004-06-06 | Raul Altman | Utilisation de meloxicame avec un agent antiplaquettaire pour le traitement du syndrome coronarien aigu et de troubles connexes |
US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US20040180815A1 (en) | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
EP1596846A2 (fr) | 2003-02-18 | 2005-11-23 | Pfizer Inc. | Inhibiteurs du virus de l'hepatite c, compositions et traitements utilisant ces inhibiteurs |
CA2516016C (fr) | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Composes d'inhibition de l'hepatite c |
JP4682140B2 (ja) | 2003-03-05 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビターペプチド類縁体 |
EP2332935A1 (fr) * | 2003-04-11 | 2011-06-15 | Vertex Pharmaceuticals Incorporated | Inhibiteurs des serine proteases, en particulier de la protease NS3-NS4A du VHC |
AU2004240704B9 (en) | 2003-05-21 | 2009-10-22 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
CN101724022A (zh) * | 2003-07-18 | 2010-06-09 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂 |
WO2005018330A1 (fr) | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Regime de dosage pour therapie contre flaviviridae |
UY28500A1 (es) * | 2003-09-05 | 2005-04-29 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc. |
US20050120398A1 (en) * | 2003-09-12 | 2005-06-02 | Vertex Pharmaceuticals Incorporated | Animal model for HCV infection |
TW200526686A (en) * | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US6933760B2 (en) | 2003-09-19 | 2005-08-23 | Intel Corporation | Reference voltage generator for hysteresis circuit |
AU2004274051A1 (en) | 2003-09-22 | 2005-03-31 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7365092B2 (en) * | 2003-10-10 | 2008-04-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
WO2005037860A2 (fr) * | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv |
AR045870A1 (es) * | 2003-10-11 | 2005-11-16 | Vertex Pharma | Terapia de combinacion para la infeccion de virus de hepatitis c |
WO2005043118A2 (fr) * | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Methode de decouverte de medicament |
CA2551074A1 (fr) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Mutants resistant a la protease hcv ns3-ns4a |
CN1893978A (zh) * | 2003-10-27 | 2007-01-10 | 沃泰克斯药物股份有限公司 | 用于hcv治疗的组合 |
JP4942485B2 (ja) * | 2003-10-28 | 2012-05-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | Fischer−fink型合成および続くアシル化による4,5−ジアルキル−3−アシル−ピロール−2−カルボン酸誘導体の製造 |
US20050119318A1 (en) | 2003-10-31 | 2005-06-02 | Hudyma Thomas W. | Inhibitors of HCV replication |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1689857A1 (fr) * | 2003-12-01 | 2006-08-16 | Vertex Pharmaceuticals Incorporated | Compositions renfermant des cellules hepatiques foetales, et procedes utiles pour le traitement de l'infection par le vhc |
JP4682155B2 (ja) | 2004-01-21 | 2011-05-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ウイルスに対して活性な大環状ペプチド |
EP1711515A2 (fr) * | 2004-02-04 | 2006-10-18 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a |
US20050187192A1 (en) | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
EP1718608B1 (fr) | 2004-02-20 | 2013-07-17 | Boehringer Ingelheim International GmbH | Inhibiteurs de la polymerase virale |
AR048413A1 (es) | 2004-02-27 | 2006-04-26 | Schering Corp | Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c |
PL1725548T3 (pl) * | 2004-03-12 | 2015-08-31 | Vertex Pharma | Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy |
PE20060309A1 (es) | 2004-05-06 | 2006-04-13 | Schering Corp | (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l |
KR101370580B1 (ko) * | 2004-06-08 | 2014-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | 약학 조성물 |
JP2008511633A (ja) | 2004-08-27 | 2008-04-17 | シェーリング コーポレイション | C型肝炎ウィルスns3セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物 |
US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
JP2009505966A (ja) * | 2005-08-02 | 2009-02-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼのインヒビター |
EP2194043B1 (fr) * | 2005-08-19 | 2013-12-25 | Vertex Pharmaceuticals Incorporated | Procédés |
AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7705138B2 (en) * | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
CN101489557B (zh) * | 2006-02-27 | 2013-12-18 | 弗特克斯药品有限公司 | 包含vx-950的共晶体和包含所述共晶体的药物组合物 |
BRPI0709568A2 (pt) * | 2006-03-16 | 2011-07-12 | Vertex Pharmaceuticals Incorporarted | processos e intermediários para preparar compostos estéricos |
EP2194039A1 (fr) * | 2006-03-16 | 2010-06-09 | Vertex Pharmceuticals Incorporated | Procédé de préparation de composés optiquement actifs |
CN101494979A (zh) * | 2006-03-20 | 2009-07-29 | 沃泰克斯药物股份有限公司 | 药物组合物 |
KR20090025187A (ko) * | 2006-03-20 | 2009-03-10 | 버텍스 파마슈티칼스 인코포레이티드 | 의약 조성물 |
US20080070972A1 (en) * | 2006-05-31 | 2008-03-20 | Kadiyala Irina N | Controlled release formulations |
MX2009009176A (es) | 2007-02-27 | 2009-09-28 | Vertex Pharma | Inhibidores de serina-proteasas. |
-
2001
- 2001-08-30 SV SV2001000617A patent/SV2003000617A/es not_active Application Discontinuation
- 2001-08-31 TW TW090121629A patent/TWI319763B/zh not_active IP Right Cessation
- 2001-08-31 TW TW097127487A patent/TWI339661B/zh not_active IP Right Cessation
- 2001-08-31 EP EP10185132.7A patent/EP2368877B1/fr not_active Expired - Lifetime
- 2001-08-31 BR BR0113666-6A patent/BR0113666A/pt not_active IP Right Cessation
- 2001-08-31 UA UA2003021834A patent/UA81600C2/uk unknown
- 2001-08-31 KR KR1020087025503A patent/KR100968295B1/ko not_active IP Right Cessation
- 2001-08-31 KR KR1020077029814A patent/KR100945975B1/ko not_active IP Right Cessation
- 2001-08-31 CA CA2419607A patent/CA2419607C/fr not_active Expired - Fee Related
- 2001-08-31 CN CN200910149350.3A patent/CN101693672B/zh not_active Expired - Fee Related
- 2001-08-31 KR KR1020087025506A patent/KR20080096718A/ko not_active Application Discontinuation
- 2001-08-31 DZ DZ013438A patent/DZ3438A1/fr active
- 2001-08-31 TW TW099107492A patent/TWI359145B/zh not_active IP Right Cessation
- 2001-08-31 MX MXPA03001780A patent/MXPA03001780A/es active IP Right Grant
- 2001-08-31 US US10/344,112 patent/US7820671B2/en not_active Expired - Fee Related
- 2001-08-31 NZ NZ569670A patent/NZ569670A/en not_active IP Right Cessation
- 2001-08-31 UA UAA200710133A patent/UA99895C2/uk unknown
- 2001-08-31 AU AU8831801A patent/AU8831801A/xx active Pending
- 2001-08-31 KR KR1020087025505A patent/KR20080104384A/ko not_active Application Discontinuation
- 2001-08-31 AT AT07012485T patent/ATE483686T1/de not_active IP Right Cessation
- 2001-08-31 EA EA200701869A patent/EA017556B1/ru not_active IP Right Cessation
- 2001-08-31 KR KR1020097022810A patent/KR20090120013A/ko not_active Application Discontinuation
- 2001-08-31 DK DK01968040.4T patent/DK1320540T5/da active
- 2001-08-31 SK SK249-2003A patent/SK2492003A3/sk unknown
- 2001-08-31 TW TW099107488A patent/TWI359144B/zh not_active IP Right Cessation
- 2001-08-31 IL IL15467101A patent/IL154671A0/xx unknown
- 2001-08-31 ES ES01968040T patent/ES2325481T3/es not_active Expired - Lifetime
- 2001-08-31 CZ CZ2003595A patent/CZ2003595A3/cs unknown
- 2001-08-31 DK DK07012485.4T patent/DK1878720T3/da active
- 2001-08-31 ES ES07012483.9T patent/ES2450815T3/es not_active Expired - Lifetime
- 2001-08-31 DE DE60143233T patent/DE60143233D1/de not_active Expired - Lifetime
- 2001-08-31 EP EP07111000A patent/EP1849797A3/fr not_active Withdrawn
- 2001-08-31 EP EP07012483.9A patent/EP1958956B1/fr not_active Expired - Lifetime
- 2001-08-31 PE PE2001000876A patent/PE20020474A1/es active IP Right Grant
- 2001-08-31 KR KR1020037002880A patent/KR100876472B1/ko not_active IP Right Cessation
- 2001-08-31 ES ES10185132.7T patent/ES2489115T3/es not_active Expired - Lifetime
- 2001-08-31 AU AU2001288318A patent/AU2001288318B2/en not_active Ceased
- 2001-08-31 EP EP10185722A patent/EP2371839A1/fr not_active Withdrawn
- 2001-08-31 CN CN2013100240570A patent/CN103232381A/zh active Pending
- 2001-08-31 EP EP20100185155 patent/EP2368901A1/fr not_active Withdrawn
- 2001-08-31 CN CN2011103464269A patent/CN102504014A/zh active Pending
- 2001-08-31 EP EP10185148A patent/EP2368878A1/fr not_active Withdrawn
- 2001-08-31 PL PL365836A patent/PL211019B1/pl unknown
- 2001-08-31 HU HU0300855A patent/HUP0300855A3/hu unknown
- 2001-08-31 PT PT01968040T patent/PT1320540E/pt unknown
- 2001-08-31 SI SI200130924T patent/SI1320540T1/sl unknown
- 2001-08-31 EP EP01968040A patent/EP1320540B9/fr not_active Expired - Lifetime
- 2001-08-31 CA CA2697205A patent/CA2697205C/fr not_active Expired - Fee Related
- 2001-08-31 ES ES07012485T patent/ES2352804T3/es not_active Expired - Lifetime
- 2001-08-31 KR KR1020107007138A patent/KR20100042296A/ko active Application Filing
- 2001-08-31 DE DE20122915U patent/DE20122915U1/de not_active Expired - Lifetime
- 2001-08-31 AR ARP010104168A patent/AR030591A1/es active IP Right Grant
- 2001-08-31 JP JP2002523884A patent/JP4689938B2/ja not_active Expired - Lifetime
- 2001-08-31 EA EA200300318A patent/EA011547B1/ru not_active IP Right Cessation
- 2001-08-31 AT AT01968040T patent/ATE431358T1/de active
- 2001-08-31 CN CN200910149349A patent/CN101696232A/zh active Pending
- 2001-08-31 CN CN2006100803265A patent/CN1869061B/zh not_active Expired - Fee Related
- 2001-08-31 TW TW099107493A patent/TW201022244A/zh unknown
- 2001-08-31 NZ NZ541302A patent/NZ541302A/en not_active IP Right Cessation
- 2001-08-31 CN CN2009101474875A patent/CN101633636B/zh not_active Expired - Fee Related
- 2001-08-31 DE DE60138717T patent/DE60138717D1/de not_active Expired - Lifetime
- 2001-08-31 WO PCT/US2001/026008 patent/WO2002018369A2/fr active Application Filing
- 2001-08-31 TW TW099107489A patent/TWI378927B/zh not_active IP Right Cessation
- 2001-08-31 KR KR1020117015737A patent/KR20110088600A/ko not_active Application Discontinuation
- 2001-08-31 KR KR1020107007135A patent/KR20100043293A/ko not_active Application Discontinuation
- 2001-08-31 EP EP07012485A patent/EP1878720B1/fr not_active Expired - Lifetime
- 2001-08-31 CN CNB018150551A patent/CN100522991C/zh not_active Expired - Fee Related
- 2001-08-31 KR KR1020087025504A patent/KR20080104383A/ko not_active Application Discontinuation
- 2001-08-31 EP EP07012484A patent/EP1876173A1/fr not_active Withdrawn
-
2003
- 2003-02-25 HR HRP20030139AA patent/HRP20030139B8/hr not_active IP Right Cessation
- 2003-02-25 EC EC2003004493A patent/ECSP034493A/es unknown
- 2003-02-27 IL IL154671A patent/IL154671A/en not_active IP Right Cessation
- 2003-02-27 NO NO20030928A patent/NO329929B1/no not_active IP Right Cessation
- 2003-02-27 ZA ZA200301641A patent/ZA200301641B/en unknown
- 2003-11-19 HK HK03108422.8A patent/HK1057758A1/xx not_active IP Right Cessation
- 2003-11-19 HK HK12103079.4A patent/HK1163061A1/xx not_active IP Right Cessation
- 2003-11-19 HK HK08104142.1A patent/HK1114090A1/xx not_active IP Right Cessation
-
2007
- 2007-01-31 EC EC2007007217A patent/ECSP077217A/es unknown
- 2007-05-30 JP JP2007143124A patent/JP2007284444A/ja active Pending
- 2007-08-30 IL IL185644A patent/IL185644A0/en unknown
-
2008
- 2008-09-08 US US12/231,982 patent/US8252923B2/en not_active Expired - Fee Related
-
2009
- 2009-07-20 CY CY20091100765T patent/CY1109216T1/el unknown
-
2010
- 2010-01-18 NO NO20100093A patent/NO20100093L/no not_active Application Discontinuation
- 2010-04-07 CL CL2010000330A patent/CL2010000330A1/es unknown
- 2010-07-12 NO NO20100999A patent/NO330807B1/no not_active IP Right Cessation
- 2010-10-25 JP JP2010238165A patent/JP5269035B2/ja not_active Expired - Fee Related
-
2011
- 2011-10-24 IL IL215891A patent/IL215891A/en not_active IP Right Cessation
- 2011-10-24 IL IL215890A patent/IL215890A0/en unknown
- 2011-10-24 IL IL215892A patent/IL215892A/en not_active IP Right Cessation
- 2011-11-10 US US13/293,812 patent/US20120064034A1/en not_active Abandoned
-
2012
- 2012-03-19 DE DE201212000015 patent/DE122012000015I1/de active Pending
- 2012-03-19 LU LU91960C patent/LU91960I2/fr unknown
- 2012-03-19 CY CY2012007C patent/CY2012007I1/el unknown
- 2012-04-03 NO NO2012006C patent/NO2012006I1/no unknown
- 2012-05-28 JP JP2012120678A patent/JP2012197289A/ja active Pending
- 2012-07-03 US US13/541,436 patent/US8529882B2/en not_active Expired - Fee Related
-
2014
- 2014-06-17 US US14/306,778 patent/US20140294763A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1320540B9 (fr) | Inhibiteurs peptidomimetiques de protease | |
AU2001288318A1 (en) | Peptidomimetic protease inhibitors | |
AU2012201015B2 (en) | Peptidomimetic protease inhibitors | |
AU2007240156B2 (en) | Peptidomimetic protease inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030331 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VERTEX PHARMACEUTICALS INCORPORATED |
|
17Q | First examination report despatched |
Effective date: 20051208 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60138717 Country of ref document: DE Date of ref document: 20090625 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20090707 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SCHMAUDER & PARTNER AG PATENT- UND MARKENANWAELTE |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20090401726 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2325481 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1057758 Country of ref document: HK |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20100216 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8364 Ref document number: 60138717 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCF Free format text: PRODUCT NAME: TELAPREVIR; REGISTRATION NUMBER/DATE: SWISSMEDIC 62082 08.09.2011 Filing date: 20120308 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: SPCF Spc suppl protection certif: C20120011 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CP Free format text: PRODUCT NAME: TELAPREVIR ET LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 12C0018 Filing date: 20120319 Ref country code: IT Ref legal event code: SPCF Ref document number: 502009901756701 Country of ref document: IT Free format text: PRODUCT NAME: TELAPREVIR(TELAPREVIR); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/720/001, 20110919 Spc suppl protection certif: 132012902033336 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: KC1 Free format text: PRODUCT NAME: TELAPREVIR EN IEDER THERAPEUTISCH EQUIVALENTE VORM DAARVAN BESCHERMD DOOR HET BASISOCTROOI, ZOALS FARMACEUTISCH AANVAARDBARE ZOUTEN EN/OF SOLVATEN VAN TELAPREVIR OF SOLVATEN VAN DERGELIJKE ZOUTEN; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: C300518 Filing date: 20120319 Extension date: 20260830 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCF Free format text: PRODUCT NAME: TELAPREVIR OCH VARJE TERAPEUTISK EKVIVALENT DAERAV SOM SKYDDAS AV GRUNDPATENTET, SA SOM FARMACEUTISKA GODTAGBARA SALTER OCH/ELLER SOLVAT AV TELAPREVIR ELLER SOLVAT AV SADANA SALTER; REG. NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 1290007-2 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: SPCF Free format text: SPC009/2012: 20120316 Spc suppl protection certif: SPC009/2012 Filing date: 20120316 Ref country code: GB Ref legal event code: CTFF Free format text: PRODUCT NAME: TELAPREVIR AND EVERY THERAPEUTICALLY EQUIVALENT FORM THEREOF PROTECTED BY THE BASIC PATENT, SUCH AS PHARMACEUTICALLY ACCEPTABLE SALTS AND/OR SOLVATES OF TELAPREVIR OR SOLVATES OF SUCH SALTS.; REGISTERED: UK EU/1/11/720/001 20110919 Spc suppl protection certif: SPC/GB12/010 Filing date: 20120316 Ref country code: IE Ref legal event code: SPCF Free format text: PRODUCT NAME: TELAPREVIR AND EVERY THERAPEUTICALLY EQUIVALENT FORM THEREOF PROTECTED BY THE BASIC PATENT, SUCH AS PHARMACEUTICALLY ACCEPTABLE SALTS AND/OR SOLVATES OF TELAPREVIR OR SOLVATES OF SUCH SALTS.; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 2012/009 Filing date: 20120316 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CR Free format text: PRODUCT NAME: TELAPREVIR ET TOUTES SES FORMES THERAPEUTIQUEMENT EQUIVALENTES PROTEGEES PAR LE BREVET DE BASE, TELLES QUE LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES D...; REGISTRATION NO/DATE IN FRANCE: EU/1/11/720/001 DU 20110919; REGISTRATION NO/DATE AT EEC: EU/1/11/720/001 DU 20110919 Spc suppl protection certif: 12C0018 Filing date: 20120319 Ref country code: FR Ref legal event code: CP Effective date: 20120321 Ref country code: FR Ref legal event code: CP Free format text: PRODUCT NAME: TELAPREVIR ET TOUTES SES FORMES THERAPEUTIQUEMENT EQUIVALENTES PROTEGEES PAR LE BREVET DE BASE, TELLES QUE LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 12C0018 Filing date: 20120319 |
|
REG | Reference to a national code |
Ref country code: IT Ref legal event code: SPCG Ref document number: 502009901756701 Country of ref document: IT Free format text: PRODUCT NAME: TELAPREVIR(TELAPREVIR); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/720/001, 20110919 Spc suppl protection certif: 132012902033336 Extension date: 20260831 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: SPCF Free format text: PRODUCT NAME: TELAPREVIRUM; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: PA2012003 Filing date: 20120316 Expiry date: 20210831 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: RPOT |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: CTFF Spc suppl protection certif: CA 2012 00007 Filing date: 20120319 Expiry date: 20260831 |
|
REG | Reference to a national code |
Ref country code: LU Ref legal event code: CCP Free format text: 91960, EXPIRES: 20260831 Spc suppl protection certif: 91960 Expiry date: 20260831 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R065 Ref document number: 60138717 Country of ref document: DE Free format text: PRODUCT NAME: TELAPREVIR UND JEDE THERAPEUTISCH AEQUIVALENTE FORM DAVON, WELCHE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE PHARMAZEUTISCH VERTRAEGLICHE SALZE UND/ODER SOLVATE VON TELAPREVIR ODER SOLVATE SOLCHER SALZE.; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 122012000015 Filing date: 20120319 Expiry date: 20210901 Extension date: 20260831 Effective date: 20120402 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T5 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: KC1 Free format text: PRODUCT NAME: TELAPREVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF SOLVAAT DAARVAN, OF SOLVATEN VAN DERGELIJKE ZOUTEN; REGISTRATION NO/DATE: EU/1/11/720/001 2011190919 Spc suppl protection certif: C300518 Filing date: 20120319 Extension date: 20260830 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: SPCG Free format text: PRODUCT NAME: TELAPREVIRUM; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: PA2012003,C1320540 Filing date: 20120316 Expiry date: 20210831 Extension date: 20260901 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCG Free format text: PRODUCT NAME: TELAPREVIR OCH FARMACEUTISKT GODTAGBARA SALTER OCH/ELLER SOLVAT AV TELAPREVIR ELLER SOLVAT AV SADANA SALTER; REG. NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 1290007-2 Expiry date: 20210901 Extension date: 20260831 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CT Free format text: PRODUCT NAME: TELAPREVIR ET LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 12C0018 Filing date: 20120319 Extension date: 20260830 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: AV Effective date: 20121212 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R067 Ref document number: 60138717 Country of ref document: DE Free format text: PRODUCT NAME: TELAPREVIR UND JEDE THERAPEUTISCH AEQUIVALENTE FORM DAVON, WELCHE DURCH DAS GRUNDPATENE SOLCHER SALZE.; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 T GESCHUETZT IST, WIE PHARMAZEUTISCH VERTRAEGLICHE SALZE UND/ODER SOLVATE VON TELAPREVIR ODER SOLVAT Spc suppl protection certif: 122012000015 Filing date: 20120319 Expiry date: 20210901 Extension date: 20260831 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: SPCG Free format text: PRODUCT NAME: TELAPREVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT AND/OR SOLVATE THEREOF OR SOLVATES OF SUCH SALTS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 2012/009 Extension date: 20260830 Effective date: 20140313 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R069 Ref document number: 60138717 Country of ref document: DE Free format text: PRODUCT NAME: TELAPREVIR UND JEDE THERAPEUTISCH AEQUIVALENTE FORM DAVON, WELCHE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE PHARMAZEUTISCH VERTRAEGLICHE SALZE UND/ODER SOLVATE VON TELAPREVIR ODER SOLVATE SOLCHER SALZE.; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 122012000015 Filing date: 20120319 Expiry date: 20210901 Extension date: 20260831 Effective date: 20140221 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 60138717 Country of ref document: DE Representative=s name: COHAUSZ & FLORACK PATENT- UND RECHTSANWAELTE P, DE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Owner name: JANSSEN PHARMACEUTICA NV, BE Effective date: 20141023 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 60138717 Country of ref document: DE Owner name: JANSSEN PHARMACEUTICA NV, BE Free format text: FORMER OWNER: VERTEX PHARMACEUTICALS INCORPORATED, 02139 CAMBRIDGE, MASS., US Effective date: 20141023 Ref country code: DE Ref legal event code: R082 Ref document number: 60138717 Country of ref document: DE Representative=s name: COHAUSZ & FLORACK PATENT- UND RECHTSANWAELTE P, DE Effective date: 20141023 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20141113 AND 20141119 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP Owner name: JANSSEN PHARMACEUTICA NV, BE Effective date: 20141124 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCG Free format text: PRODUCT NAME: TELAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 62082 08.09.2011 Spc suppl protection certif: C01320540/01 Filing date: 20120308 Extension date: 20260830 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CA Effective date: 20150113 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: JANSSEN PHARMACEUTICA NV, BE Free format text: FORMER OWNER: VERTEX PHARMACEUTICALS INCORPORATED, US Ref country code: CH Ref legal event code: SPCM Owner name: JANSSEN PHARMACEUTICA NV, BE Free format text: FORMER OWNER: VERTEX PHARMACEUTICALS INCORPORATED, US Spc suppl protection certif: C01320540/01 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: CTFG Free format text: PRODUCT NAME: TELAPREVIR OG FARMACEUTISK ACCEPTABLE SALTE OG/ELLER SOLVATER AF TELAPREVIR ELLER SOLVATER AF SADANNE SALTE; REG. NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: CR 2012 00007 Filing date: 20120319 Expiry date: 20210831 Extension date: 20260831 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: SP73 Owner name: JANSSEN PHARMACEUTICA NV; BE Effective date: 20150605 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: SPCT Owner name: JANSSEN PHARMACEUTICA NV, BE Free format text: PRODUCT NAME: TELAPREVIR ET LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 12C0018 Filing date: 20120319 Extension date: 20260830 Ref country code: FR Ref legal event code: SPCT Owner name: JANSSEN PHARMACEUTICA NV, BE Free format text: PRODUCT NAME: TELAPREVIR ET LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 12C0018 Filing date: 20120319 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20150810 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFG Free format text: PRODUCT NAME: TELAPREVIR OR PHARMACEUTICALLY ACCEPTABLE SALTS AND/OR SOLVATES OF TELAPREVIR OR SOLVATES OF SUCH SALTS.; REGISTERED: UK EU/1/11/720/001 20110919 Spc suppl protection certif: SPC/GB12/010 Filing date: 20120316 Extension date: 20260830 Effective date: 20160311 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20160810 Year of fee payment: 16 Ref country code: LU Payment date: 20160823 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20160823 Year of fee payment: 16 Ref country code: CH Payment date: 20160812 Year of fee payment: 16 Ref country code: FI Payment date: 20160809 Year of fee payment: 16 Ref country code: IT Payment date: 20160822 Year of fee payment: 16 Ref country code: MC Payment date: 20160811 Year of fee payment: 16 Ref country code: GB Payment date: 20160831 Year of fee payment: 16 Ref country code: DK Payment date: 20160810 Year of fee payment: 16 Ref country code: IE Payment date: 20160809 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20160829 Year of fee payment: 16 Ref country code: GR Payment date: 20160812 Year of fee payment: 16 Ref country code: AT Payment date: 20160809 Year of fee payment: 16 Ref country code: SE Payment date: 20160811 Year of fee payment: 16 Ref country code: FR Payment date: 20160816 Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: SPCG Spc suppl protection certif: 470 Extension date: 20260831 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20160815 Year of fee payment: 16 Ref country code: ES Payment date: 20160811 Year of fee payment: 16 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160831 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60138717 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: SPCR Ref document number: 431358 Country of ref document: AT Kind code of ref document: T Free format text: PRODUCT NAME: TELAPREVIR UND JEDE THERAPEUTISCH AEQUIVALENTE FORM DAVON, WELCHE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE PHARMAZEUTISCH VERTRAEGLICHE SALZE UND/ODER SOLVATE VON TELAPREVIR ODER SOLVATE SOLCHER SALZE; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 9/2012 Filing date: 20120416 Expiry date: 20210831 Extension date: 20260831 Effective date: 20180315 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20170831 Ref country code: LT Ref legal event code: MM9D Effective date: 20170831 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20170901 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 431358 Country of ref document: AT Kind code of ref document: T Effective date: 20170831 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20170831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20180430 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180305 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180228 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20180410 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20170831 Ref country code: BE Ref legal event code: PD Owner name: JANSSEN PHARMACEUTICA N.V.; BE Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), AFFECTATION / CESSION; FORMER OWNER NAME: VERTEX PHARMACEUTICALS INCORPORATED Effective date: 20141023 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCC Spc suppl protection certif: 1290007-2 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170901 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180301 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: SPCI Free format text: PRODUCT NAME: TELAPREVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT AND/OR SOLVATE THEREOF OR SOLVATES OF SUCH SALTS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 2012/009 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20181024 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20180816 Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: SPCG Free format text: PRODUCT NAME: TELAPREVIR SI TOATE FORMELE ECHIVALENTE TERAPEUTIC ALEACESTUIA, PRECUM SARURI SI/SAU SRO EU/1/11/720/001; DATE OF NATIONAL AUTHORISATION: 20110919; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/720/001; DATE OF FIRST AUTHORISATION IN EEA: 20110919 OLVATI ACCEPTABILI FARMACEUTIC SAU SOLVATI AI UNOR ASTFEL DE SARURI; NATIONAL AUTHORISATION NUMBER: Spc suppl protection certif: C 2012 005 Extension date: 20260831 Effective date: 20180524 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170901 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170901 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: SPCI Free format text: PRODUCT NAME: TELAPREVIR OR PHARMACEUTICALLY ACCEPTABLE SALTS AND/OR SOLVATES OF TELAPREVIR OR SOLVATES OF SUCH SALTS.; REGISTERED: UK EU/1/11/720/001 20110919 Spc suppl protection certif: SPC/GB12/010 Filing date: 20120316 Effective date: 20170831 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60138717 Country of ref document: DE Free format text: PRODUCT NAME: TELAPREVIR UND JEDE THERAPEUTISCH AEQUIVALENTE FORM DAVON, WELCHE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE PHARMAZEUTISCH VERTRAEGLICHE SALZE UND/ODER SOLVATE VON TELAPREVIR ODER SOLVATE SOLCHER SALZE.; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: 122012000015 Filing date: 20120319 Expiry date: 20210901 Extension date: 20260831 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: SPCL Spc suppl protection certif: C01320540/01 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190831 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: CTFL Free format text: PRODUCT NAME: TELAPREVIR OG FARMACEUTISK ACCEPTABLE SALTE OG/ELLER SOLVATER AF TELAPREVIR ELLER SOLVATER AF SADANNE SALTE; REG. NO/DATE: EU/1/11/720/001 20110919 Spc suppl protection certif: CR 2012 00007 Filing date: 20120319 Expiry date: 20210831 |